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Complex diseases, such as cancer and inflammatory bowel disease, are caused by a combination 
of genetic and environmental factors. The advent of next-generation sequencing (NGS) 
technology allowed the genome-wide investigation of the underlying genetic causes of complex 
disorders. Analysis of the large amount of data generated by NGS is computationally intensive 
and require new computational methods. One of the current problems in genomic data analysis is 
the lack of computational methods for functional annotation of DNA sequence variants (DSVs), 
especially regulatory DNA sequence variants (rDSVs). In recent years, rDSVs have been shown 
to be the primary cause of complex diseases, supported by the fact that functional regulatory sites 
are more polymorphic than coding regions, and that rDSVs vastly outnumber coding variants. 
Also, GWAS studies of complex traits have shown that SNPs with the strongest association 
signals lie outside known genes in non-coding regions of the genome. 
This dissertation contributes to a solution for the lack of computational methods for the 
analysis of DNA sequence variants. Two novel computational methods for the analysis of DSVs 
are proposed here: 1) an algorithm, called is-miRSNP, IRUWKHSUHGLFWLRQRIWKHHIIHFWRI¶875
DSVs on miRNA binding, 2) a pipeline for the functional annotation of DSVs using NGS. The 
is-miRSNP algorithm uses a binding-energy approach for the prediction of DSVs effects on 
miRNA binding. The algorithm is flexible enough to process large amounts of data and can be 
easily integrated in existing pipelines. Experiments using a manually curated set of 
experimentally validated DSVs-miRNA showed that is-miRSNP outperforms all most popular 
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existing methods. The pipeline for functional annotation of functional DSVs utilizes state-of-the-
art existing computational methods. The pipeline has been applied to an effector memory T cell 
RNA-Seq dataset that is related to inflammatory bowel disease and has identified biologically 
relevant genes and isoforms that are differentially expressed upon treatment with Prostaglandin 
E2. Important pathways and biologically relevant DSVs were also identified and recovered. 
These methods have the potential to help clinicians and researchers analyze and interpret 
genomic datasets, and might in the future help the development of new diagnostics methods and 
treatments.  
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1.0  INTRODUCTION 
Genetic variation among individuals can be classified into three categories: 1) single nucleotide 
variation (SNV); 2) intragenic insertion and deletion (INDEL); 3) structural variants that include 
translocations and copy number variation (Lee, Arvai, & Jones, 2015). The most common type 
of genetic variation is SNV. Whole genome sequencing of 2,636 individuals identified 20 
million SNVs, whereas only 1.5 million INDELs were found (Gudbjartsson et al., 2015). This 
dissertation will focus on the study of SNVs, due to their higher frequency and bigger relevance 
to the understanding of human genetic variation. 
SNVs can be further classified based on two criteria: population frequency and genomic 
location. Based on the first criteria SNVs can be split into single nucleotide polymorphisms 
(SNPs) and mutations. The distinction between these two is based on allelic frequency in the 
general population. SNPs have an allelic frequency greater or equal to 1%, whereas mutations 
are rarer with a frequency of less than 1% (Brookes, 1999).  It is important to note that in this 
study, the term SNV will be used as no distinction is being made regarding the allelic frequency 
of a variant in the population. Using genomic location SNVs can be divided into coding and 
regulatory DNA Sequence Variants (DSVs). Coding variants are located only in exons, whereas 
regulatory variants (rDSV) can be found in the rest of the genome SURPRWHUUHJLRQV¶875V
5¶875VLQWURQVDQGLQWHUJHQLFUHJLRQV 
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Coding variants can have a direct effect on an individual¶V phenotype. It can act by 
changing the quantity of the quality of a protein (Buckland, 2006). Alterations in protein quality 
are the result of changes in the mRNA sequence, which in turn translate into modifications of the 
protein¶V amino acid sequence and/or protein structure. Changes in quantity are the result of 
modifications on the rate which the mRNA is translated into protein.  
Regulatory coding variants do not directly affect the protein quality, but instead alter 
mRNA abundance by changing gene expression. There are 3 ways that a rDSV can affect gene 
expression: 1) by altering transcription factor binding sites (Deplancke, Alpern, & Gardeux, 
2016); 2) by changing microRNA binding sites (Mishra, Mishra, Banerjee, & Bertino, 2008); 3) 
by altering splice-sites (Baralle & Baralle, 2005).  
Transcription factors (TF) are DNA-binding proteins, which bind to specific short DNA 
sequences usually located in the promoter regions of genes. The binding of these proteins can 
lead to activation or repression of the target gene (Latchman, 1997). DSVs can potentially alter 
the DNA sequence of a gene promoter region and consequently, create or destroy a TF binding 
site. One of the first accounts of a DSV effecting the binding of a TF was hypothesized by Orkin 
and coworkers in 1982 (Deplancke et al., 2016; Orkin et al., 1982). The authors suggested that a 
DSV (C to T, at position 87 of the transcription start site of the Beta Hemoglobin gene) was 
affecting the transcriptional recruitment of some unknown TF. Finally, in 1993, Miller and 
Biecker showed that the unknown TF affected by the DSV was the Kruppel like Factor 1 protein 
(Miller & Bieker, 1993). 
MicroRNAs (miRNAs) are short (~22 nt) endogenous RNAs that control gene-expression 
in eukaryotes (Ambros, 2004; Bartel, 2004). Binding of these short non-coding RNAs to the 
¶875 of a messenger RNA (mRNA) leads to the P51$¶V degradation. Recently, several 
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polymorphisms that affect miRNA binding (miRSNPs) have been identified (Mishra et al., 
2008). One example is the DSV &WR7DWSRVLWLRQRIWKH¶875RIWKHKXPDQGLK\GURIRODWH
reductase (DHFR) gene, which impairs the binding of miR-24 at this particular site and leads to 
the overexpression of the DHFR gene. The DHFR gene is responsible for metabolizing the 
chemotherapeutic drug methotrexate. Such finding has important clinical implications as tumors 
which have this DSV are resistance to methotrexate and should be treated with an alternative 
chemotherapeutic regimen (Mishra et al., 2007).   
Transcription in eukaryotes is a multi-step process: it begins with the transcription of a 
DNA template into an unprocessed RNA molecule called the pre-mRNA. Next, the pre-mRNA 
is processed; its introns and sometimes exons are removed by a process called splicing. The 
spliced pre-mRNA is the mature form of the mRNA, and will be later translated into a protein 
(Clancy, 2008). 
Splicing is an essential step in the formation of mRNA and will consequently impact the 
protein that will be synthetized. Therefore, missplicing of genes lead to diseases like leukemia, 
hematolymphoid neoplasias, retinitis pigmentosa and microcephalic osteodysplastic primordial 
dwarfism type 1 (MODPD1) (Mohamed et al., 2014; Singh & Cooper, 2012).  A common cause 
for missplicing is the presence of DSVs that will either create or destroy a splice-site. It is 
estimated that from those point mutations that alter splice-sites, 15% will result in some type of 
genetic disorder (Baralle & Baralle, 2005).  
Monogenic Mendelian disorders, such as cystic fibrosis, Tay-Sachs disease, and sickle 
cell anemia, have been linked to specific protein coding DSVs. However, only very few 
polygenic diseases have been liked to specific protein coding DSVs in a single gene (this is the 
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case of BRCA1 mutations in breast cancer, which only comprises of a very small percentage of 
all breast cancer cases).  
Monogenic Mendelian disorders only comprise a small portion of all human disorders 
with most human diseases being clDVVLILHGDVµFRPSOH[GLVRUGHUV¶&RPSOH[GLVHDVHs are caused 
by a combination of genetic and environmental factors. Examples of complex diseases are 
FDQFHUV LQIODPPDWRU\ ERZHO GLVHDVH DVWKPD 3DUNLVRQ¶V GLVHDVH $O]KHLPHU¶V GLVHDVHV
(Buckland, 2006; Hunter, 2005).  
The small number of causal protein-coding variants associated with complex diseases led 
to the hypothesis that majority of disease-causing variants are probably located in the non-coding 
DNA (Cobb, Busst, Petrou, Harrap, & Ellis, 2008).  The hypothesis that rDSVs are the main 
cause for complex diseases is further support by the fact that functional regulatory sites are more 
polymorphic than coding regions (Pampin & Rodriguez-Rey, 2007). Also, rDSVs vastly 
outnumber coding variants, as less than two percent of the genome is composed by exons 
(Scacheri & Scacheri, 2015). Therefore, is likely that phenotypes are a consequence of variation 
in the expression of genes rather than the expression of different genes, and that rDSVs are the 
main source of genetic variation (Buckland, 2006; Hudson, 2003; Knight, 2005; Scacheri & 
Scacheri, 2015; Tak & Farnham, 2015).  
1.1 THE PROBLEM 
As discussed in the introduction, various complex diseases are likely caused by rDSVs that have 
some effect on the regulation of gene expression. Unfortunately, the identification and functional 
interpretation of rDSVs is hard (Buckland, 2006; Hudson, 2003; Knight, 2005; Pampin & 
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Rodriguez-Rey, 2007). There are two main challenges in identifying, evaluating and prioritizing 
rDSVs: 1) lack of methods to accurately evaluate and prioritize rDSVs, especially variants that 
affect miRNA binding sites; 2) need for genomic data analysis pipelines that can identify, 
evaluate and prioritize rDSVs. 
The first challenge deals with identification and prioritization of rDSVs that affect 
miRNA binding sites. Various methods and datasets for predicting rDSVs that alter transcription 
factor binding sites and splice-sites already exist. However, available computational methods for 
predicting the effect of DSVs that alter miRNA binding sites are not accurate and results are hard 
to interpret. 
The second problem relates to lack of analysis pipeline that focus on the identification 
and prioritization of DSVs found in genomic datasets. With the abundance of public genomic 
datasets and the popularization of NGS, methods that can properly integrate and analyze various 
genomic datasets are in great need.  
1.1.1 Predicting and prioritizing rDSVs that affect miRNA binding sites 
The Human Genome Project revealed that ~99% of the genome is composed of non-coding 
regions. The importance of these non-coding regions became self-evident when comparative 
genomics revealed that a great number of these regions are conserved among mammalians. In 
recent years, genome-wide association studies (GWAS) showed that the majority of complex 
trait-associated loci are in non-coding regions (Kellis et al., 2014).  
The lack of understanding of the biology of non-coding regions associated with its 
evolutionary and medical importance lead to the creation of Encyclopedia of DNA Elements 
(ENCODE) project. The ENCODE project is a big international initiative that has as the main 
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goal to identify and characterize functional elements within the human genome (Consortium, 
2012; Diehl & Boyle, 2016; Kellis et al., 2014; Pazin, 2015; Qu & Fang, 2013).  
Using high-throughput NGS-based assays (RNA-seq, CAGE, RNA-PET, ChIP-Seq, 
DNase-seq, FAIRE-seq, histone ChIP-Seq, MNase-seq, RRBS), the ENCODE project has 
identified and characterized the following functional elements from 147 different cell types: 
RNA transcribed regions, protein-coding regions, TF binding sites, chromatin structure and DNA 
methylation (Consortium, 2012; Qu & Fang, 2013).   
The ENCODE project also investigated the potential effect of DSVs in the function of 
genomic functional elements. For protein-coding genes, DSVs that are likely to disrupt splice-
sites, introduce frame-shift or lead to protein truncation (premature stop of translation) were 
found. Variants that are in TF binding regions and that are likely to disrupt binding were also 
identified (Consortium, 2012). 
The functional understanding of rDSVs that affect splice-sites and TF binding was 
greatly enhanced by the ENCODE project. Furthermore, these two categories of rDSVs have 
been widely investigated by other groups and several computational tools to predict their effect 
have been created.  
Despite the ample efforts to characterize rDSVs, variants that can potentially alter 
miRNA binding have not been widely studied. The reason for such are two: 1) complicated 
nature of PL51$ ELQGLQJ ZKLFK GRQ¶W IROORZ DV VWULFW UXOHV DV 7) ELQGing; 2) technology 
difficulties in experimentally determining miRNA biding sites, despite the newly developed 
NGS-based assays PAR-CLIP (Hafner et al., 2010), HITS-CLIP (Licatalosi et al., 2008) and 
iCLIP (Konig et al., 2010).  
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Recently, computational tools IRUSUHGLFWLQJWKHHIIHFWRIU'69¶VLQPL51$ELQGLQJVLWHV
were created. However, these tools have the following problems: 1) they are mostly databases 
that host a collection of pre-computed predictions. Thus, they do not allow users to run 
predictions in a set of customized rDSVs, making them not practical for the analysis of large 
genomics datasets; 2) results of available methods are difficult to interpret, making rDSV 
prioritization a hard task.  
1.1.2 Functional evaluation and prioritizing of DSVs in genomic datasets 
Genomic and clinical genomic datasets focus on protein-coding variants, mainly because 
functional interpretation of coding variants is easier. (Consortium, 2012; Macarthur, 2012). In 
contrast to coding DSVs, variants in the non-coding regions of the genome usually have small or 
undetectable impacts on gene expression due to functional redundancy. Therefore, interpretation 
of rDSVs in a genomic-scale data poses great challenge (Macarthur, 2012). 
The decreasing cost of genomic assays as well major public initiatives like The Cancer 
Genome Atlas (TCGA), ENCODE, and The International Cancer Genome Consortium (ICGC) 
lead to a vertiginous increase in the amount of publicly available genomic datasets (Kannan et 
al., 2016). 
One of the findings of the ENCODE project is that RNA production and processing is 
quantitatively correlated with transcription factor binding at gene promoters and with the state of 
the chromatin (Consortium, 2012). These findings suggest that regulation of gene expression is a 
complex process, and that correct functional prediction of the effect of a DSV should consider 
the current state of the cell (i.e. which TFs, genes and miRNAs are expressed as well as the state 
of chromatin). The most accurate way to determine the current state of a cell is to integrate 
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various types of genomic data, which is, fortunately, possible today due to the wealth of public 
data available. However, most of analysis methods and pipelines available today are designed to 
take into consideration only one type of genomic data, which lead in many cases to wrong 
functional interpretation of a DSV. 
1.2 THE APPROACH 
This dissertation address two main problems in the current field of computational genomics: 1) 
the lack of computational methods capable of accurately predicting the effect of rDSVs on 
miRNA binding and 2) the inexistence of computational pipelines that can functionally predict 
the effect of DSVs considering the current state of cells. 
The first problem is addressed by proposing a new algorithm called is-mirSNP. It uses 
binding energy as a measure of how strong a mRNA will bind to miRNA. The binding energy of 
two different sequences with a given miRNA are calculated. One of sequences contains the 
reference allele, whereas the other has the DSV of interest. The binding energy difference 
between the two mRNA-miRNA pairs are compared, and if statistically significant the DSVs is 
considered to alter miRNA binding. The is-mirSNP algorithm can be divided in two main parts: 
a) estimation of background binding energy distributions, b) scoring the effect of a DSVs in 
miRNA binding. 
In the first step, two different background distributions are empirically estimated: 
background binding distribution, and the distribution of log ratios of binding energy p-values. 
Each of the two background distributions are calculated for each miRNA. The estimation of the 
background distributions need to happen only once, and are required by the scoring of a DSV. 
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First, the background binding distribution is calculated. This distribution is comprised of the 
binding energies of a given miRNA with all ¶875VHTXHQFHV in the reference genome. After 
this is completed, the distribution of log ratios of p-values is computed. First, two binding 
energies are calculated: a) the binding energy of a miRNA with a sequence containing the 
reference alleles, and b) the binding energy of a miRNA with a sequence containing the DSVs of 
interest. For each of these energies, a p-value is obtained using the previously computed 
background energy distribution. Then, the log-ratio of the two p-values is computed. For the 
computation of the distribution of log-ratios of binding energy p-values, this process is repeated 
50,000 GLIIHUHQWNQRZQ¶875'69V. 
The second step of the algorithm consists of scoring a DSV. The main purpose of scoring 
a DSV is to evaluate how it would affect miRNA. For such, the binding energy of a DSV is 
compared to the binding energy of a reference allele. The magnitude of the energy difference 
between alleles is important, but not meaningful if it does not translate into actual binding. A 
great proportion of DSVs will change miRNA binding energy to some extent, but only a small 
portion will have a positive or negative effect on binding. The scoring step of the algorithm 
works in the following way: 1) Sequences for all possible k-mers are generated: one containing 
the reference allele and another containing the alternative allele; 2) Binding energy for all k-mers 
are calculated; 3) The lowest binding energy for k-mers containing reference allele, and lowest 
binding energy for k-mers containing the DSV allele are kept; 3) P-values for lowest binding 
energy for reference and DSV is computed from background distribution; 4) Log p-value ratio is 
calculated; 5) P-value of log p-value ratio is calculated using the distribution of log ratios of 
binding energy p-values. This process is initially done for the following k-mers: 7-mers, 8-mers 
and l-mers (where l is the length of the miRNA being tested). The algorithm stops whenever the 
  10 
p-value of the log-pvalue ratio is significant (p-value < 0.05), otherwise results for the last step 
(l-mer evaluation) are reported. The is-mirSNP algorithm gives the users a p-value for each DSV 
that is evaluated. In addition, the algorithm reports the binding energies for each allele and their 
p-values, which greatly helps the interpretation of the results. 
The second problem addressed in this dissertation is the lack of analysis pipelines that 
can functionally annotate DSVs. The pipeline proposed here integrates GWAS with gene 
expression data (RNA-Seq), and functionally annotates inferred DSVs. The pipeline has 3 steps: 
1) RNA-Seq analysis; 2) DSV Annotation; 3) Integration of GWAS with expression data.  
The first step in the pipeline is RNA-Seq analysis. RNA-Seq analysis starts by assessing 
the quality of data. Metrics utilized for quality-control are number of reads, and overall reads 
PHRED scores. Reads with low quality are either trimmed (if low quality regions are only in the 
end and/or beginning of reads) or discarded. At this step, removal of adapter sequences is done if 
applicable. After the quality-control step, reads are mapped to the reference genome, and gene 
and isoform expressions are quantified. Next, tests for differentially expressed genes are 
performed. The number of tests or which tests that need to be performed are defined by the 
biological questions that need to be answered as well as the experimental design. 
The second step consists of finding DSVs that are inside or in the surroundings of 
differentially expressed genes. DSVs in WKHH[RQVLQWURQV¶875¶875DQGSURPRWHUUHJLRQV 
(5kp upstream and 5kb downstream) are identified.  
Next, previously identified DSVs are further filtered. Tag-DSVs (DSVs that are 
statistically associated with the complex disease in question) are obtained from relevant existing 
GWAS studies. Then, linkage-disequilibrium (LD) analysis are run between tag-DSVs and 
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identified DSVs. DSVs with a LD score > 0.8 are considered to be in LD with a Tag-SNP and 
are functionally annotated.  
Functional annotation of DSVs will depend on the region where a DSV is found: DSVs 
in exons are functionally annotated for their potential impact in protein sequence and structure, 
DSVs in introns are annotated for splice-sites and effect in TF binding, DSVs in ¶875 DQG
promoter regions are annotated for effect in TF binding, and '69VLQ¶875DUHDQQRWDWHGIRU
effect in miRNA binding. In the assessment of TF binding only expressed in the RNA-Seq 
dataset TFs are considered. DSVs that are in LD with a Tag-SNP and are predicted to have any 
function are reported. 
After implementation, the analysis pipeline just described will be tested on a RNA-seq 
datasets that mimics the behavior of Th17 lymphocytes in inflammatory bowel disease patients.   
1.2.1 THESIS 
The main thesis of this dissertation is that the new algorithms and methods presented here can 
correctly identify, assign function to, and prioritize DSVs.  
Using manually curated validation datasets and a novel RNA-seq dataset, the following 
conjectures will be evaluated: 
Claim 1. The is-miRSNP algorithm is capable of correctly identifying validated DSVs 
known to affect miRNA binding. The algorithm presented here not only performs better than 
existing tools, but the results obtained are easier to interpret. The algorithm can be used to 
evaluate novel and existing data.  
Claim 2. Our pipeline for identification of functional DSVs can identify functional 
relevant variants from RNA-Seq data, when integrated to existing GWAS data. Results obtained 
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from our pipeline when applied to a novel RNA-Seq experiment leads to biologically meaningful 
results. 
1.3 SIGNIFICANCE 
This section discusses the significance of the work if the above hypothesis and claims are 
supported by experimental evidence. The is-mirSNP algorithm deals with the problem of 
predicting whether a DSV can affect a miRNA binding site. From a bioinformatics stand point, 
we present a novel algorithm that uses binding energy to predict the effect of a given DSV. The 
novelty of our approach consists of computing the background binding energy distributions and 
the background distributions of the log-ratio of the p-values of a pair of binding energies. This 
approach allows for the calculation of p-values which are easy to interpret. The algorithm is fast 
and robust. It can be easily integrated into existing analysis pipelines, and can be used to predict 
DSVs found by large genomic datasets. From a medical perspective is-mirSNP will allow 
scientists to accurately assign function to a vast number of rDSVs that would not have been 
functionally annotated otherwise. Therefore, predictions done by is-mirSNP algorithm will allow 
for more accurate interpretation of clinical and research genomic datasets, which in turn can lead 
to the elucidation of molecular mechanisms of diseases.  
A pipeline that analyzes and functionally annotates DSVs is also proposed. It consists of 
a new bioinformatics approach to the analysis and integration of genomic datasets. The pipeline 
puts together existing computational tools, and utilizes existing methods in a novel way. It can 
leverage and interpret existing data. From a biomedical stand-point the analysis pipeline 
described can elucidate and ascribe function to DSVs that would otherwise not have been 
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associated to disease. Identification of such variants have several potential clinical benefits as 
such DSVs can be used for new diagnostic tests, to better estimate prognostics or even be targets 
of new therapeutics.  
 
 
1.4 DISSERTATION OVERVIEW 
This dissertation has the following structure: 
 Chapter 2 describes in detail our algorithm for identification and prioritization of DSVs 
that can affect miRNA binding sites. It also describes datasets used for algorithm evaluation and 
comparison to existing tools.  
Chapter 3 provides detailed information about our pipeline for identification of  
functional relevant variants from RNA-Seq data, when integrated to existing GWAS data 
Chapter 4 presents the application of the pipeline described in Chapter 3 to an effector 
memory T cell RNA-Seq dataset that is related to inflammatory bowel disease. 
  14 
2.0  PREDICTION OF MIRNA BINDING SITES 
2.1 BACKGROUND 
MicroRNA (miRNAs) are endogenous non-coding small RNAs that play a very important role in 
the regulation of gene expression. The principal characteristics of miRNAs are their length of 
approximately 22 nucleotides and the fact that they are produced by two RNaseIII proteins, 
Drosha and Dicer (Ha & Kim, 2014).  
7KHPL51$ELRJHQHVLVJHQHUDOO\ IROORZVD µOLQHDU¶SDWKZD\DOWKRXJKPL51$-specific 
modifications to this pathway are not uncommon (Winter, Jung, Keller, Gregory, & Diederichs, 
2009)7KHµOLQHDU¶FDQRQLFDOSDWKZD\VWDUWVZLWKWKHSURGXFWLRQRIDSULPDU\PL51$WUDQVFULSW
called the pri-miRNA. Then, this pri-miRNA is cleaved in the nucleous by the Pasha (Drosha-
DGCR8) complex. The cleaved product, now called a pre-miRNA, is exported to the cytoplasm 
where it is cleaved one more by the RNase Dicer, resulting in a mature miRNA with a length of 
approximately 22 nucleotides. The miRNA is loaded together with the Argonaute (AGO2) 
protein into the RISC complex where it determines by complimentary which messenger RNA 
(mRNA) will be degraded (Winter et al., 2009).miRNAs play an important role in regulation of 
gene expression  with at least 60% of all genes being regulated by these small non-coding RNAs 
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(Friedman, Farh, Burge, & Bartel, 2009). Several studies have showed the importance of 
miRNAs in diseases like cancer and neurodevelopmental disorders (Ha & Kim, 2014)  
The recognition of miRNA binding-sites follows certain rules but several exceptions have 
been reported (Clark et al., 2014)PL51$ELQGLQJXVXDOO\RFFXUVLQ WKH¶XQWUDQVODWHGUHJLRQ
¶875 RI P51$V )RU FDQRQLFDO PL51$ ELQGLQJ PD[LPXP FRPSOHPHQWDU\ RI D VKRUW ¶
region on the miRNA to its target is necessary (Ellwanger, Buttner, Mewes, & Stumpflen, 2011; 
Landi, Barale, Gemignani, & Landi, 2011). This short region usually spans positions 2-8 of the 
¶ end of the miRNA and is known as the µVHHG¶ (Clark et al., 2014). A maximum of one 
mismatch between the seed and its target is tolerated. The pairing of G with T is also allowed in 
the mRNA-miRNA duplex (Landi et al., 2011). Ellwanger et al. investigated the minimal set of 
seeds needed for miRNA binding. They identified a set of 6 seed types, which consist of seeds 
from six to eight nucleotides long and with mismatches at different positions. Interestingly, the 
majority of functional seeds were six nucleotides long, but most target prediction algorithms 
focused on seven of eight nucleotide long seeds (Ellwanger et al., 2011). In addition to canonical 
seed interactions, non-standard binding in which contiguous base pairing is interrupted by bulges 
KDVEHHQUHSRUWHGµ6HHG-OHVV¶LQWHUDFWLRQVRIWDUJHWVORFDWHGRXWVLGHWKH¶875ZKLFKZHUHQRQ
conserved amongst various species has also been observed (Clark et al., 2014) . 
NGS technologies allowed the high-throughput study of miRNAs and their effects in a 
large scale. Utilizing methods like PAR-CLIP, HITS-CLIP and iCLIP researchers can investigate 
miRNA-target binding in a whole-genome scale (Danan, Manickavel, & Hafner, 2016; Darnell, 
2010; Konig et al., 2011) . However, the enormous amount of data generated by these 
technologies creates data analysis challenges, which require novel computational tools (T. Wang 
et al., 2015). 
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Several algorithms that predict miRNA binding sites have been developed. These 
algorithms look for features such as conservation of binding sites, patterns in seed matching, and 
energetic stability of the miRNA-mRNA pair (Landi et al., 2011). TargetScan checks the 
conservation of sites among different species in conjunction with the thermodynamic stability of 
the miRNA-mRNA pair (Lewis, Burge, & Bartel, 2005). Miranda utilizes thermodynamic 
stability, base pairing information and conservation information to assess miRNA-mRNA 
pairing (Enright et al., 2003). RNAhybrid calculates the optimal energy between the two RNA 
sequences (Rehmsmeier, Steffen, Hochsmann, & Giegerich, 2004). MicroInspector uses a sliding 
window to check for complementary between the miRNA and its target (Rusinov, Baev, Minkov, 
& Tabler, 2005). Pictar checks for complementary in the miRNA seed region, calculates the 
binding energy and calculates the likelihood of binding using a Hidden Markov Model (Krek et 
al., 2005). Diana-microT not only calculates the binding energy, but also considers conservation 
and biological pathway information (Maragkakis et al., 2009).  
Single-nucleotide polymorphisms can affect the binding between miRNA and mRNA by 
either increasing or decreasing the binding energy of a given miRNA and mRNA (Landi et al., 
2011).  Recently, several databases that contain SNPs, which can potentially alter miRNA 
binding sites, were created. The most widely used tools are PolymiRTS (Ziebarth, Bhattacharya, 
Chen, & Cui, 2012), mirSNP (C. Liu et al., 2012), mrSNP (Deveci, Catalyurek, & Toland, 2014), 
mirsnpscore (Thomas, Saito, & Saetrom, 2011) and miRNASNP2 (Gong et al., 2015). These 
databases utilize the previously described miRNA target prediction tools to detect the formation 
or disruption of binding sites. All the databases follow the same approach: they scan the entire 
genome against a SNP database like dbSNP and store the entire results. Although 
computationally efficient this approach only permits users to retrieve results for SNPs that are 
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already known.  Users cannot obtain predictions for novel DSVs that are not available in 
databases but present in their datasets. Pre-computation of results usually become outdated, if 
databases are not diligently updated. This is especially true as more genomic data is being 
generated at a faster pace.  Another problem with pre-computed, web-tools is that querying large 
amounts of SNPs is usually difficult or impossible. Integration of such tools with existing 
pipelines for analysis of whole genome data is also not possible.  Deveci et al. tried to address 
these issues by developing a tool capable of handling custom queries, so that new SNPs could be 
assessed (Deveci et al., 2014). However, mrSNP still suffers of main drawbacks. First, it does 
not provide users with a score or probability of a SNP altering a miRNA-binding site. Second, it 
LV RQO\ FDSDEOH RI VFDQQLQJ ¶875 DQG VHDUFKLQJ IRU 613V WKDW DOWHU FDQRQLFDO ELQGLQJ It is 
important to note that the mrSNP website has been down since the beginning of this work, 
therefore it has not been possible to obtain a copy of the code. 
Most the algorithms and tools created for predicting the effect of DSVs in miRNA 
binding are web-based and work like a database where users can query pre-computed results. 
Usually, these algorithms are run for a specific version of a SNP database like dbSNP. There is 
also the problem with the interpretation of the results obtained from existing tools: most of the 
time the meaning of the predictions are not clear as no intuitive score is generated. This poses a 
challenge for users trying to prioritize and rank a great number of results obtained from genomic 
analysis.  
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2.2 METHODS 
Our algorithm uses a principle that is similar to the one presented by is-rSNP (Macintyre, Bailey, 
Haviv, & Kowalczyk, 2010).  Is-rSNP is an algorithm designed to predict the effect of regulatory 
DSVs on transcription factor binding sites. Briefly, it estimates the background binding 
distributions of a transcription factor from its position-scoring matrix (PWM). Sequences 
containing the alleles of interest are scored using the very same PWM. The two scores are 
compared and statistical significance is calculated.  
The nature of TF binding and miRNA binding is different, with miRNAs showing more 
binding motif variation which does not allow for the computation of PWMs. The is-mirSNP 
algorithm takes a unique approach to the statistical estimation of miRNA binding variation. This 
approach allows the proper separation between binding and non-binding, and the accurate 
estimation of the effects of a DSV. Binding energy is used as a measure of direct miRNA-
binding, and the background distributions are empirically estimated by a novel algorithm 
(Material and Methods sections 2.2.1 and 2.2.2). The scoring method of is-rSNP and our 
algorithm follow the same principle; both methods calculate scores for sequences with and 
without the DSV. The scores are then compared and statistical significance is calculated using 
the pre-computed background distributions (Material and Methods sections 2.2.3). 
2.2.1 Computation of miRNA binding energy background distributions 
The first step in the prediction of the functional effect of a DSV in miRNA binding is the 
calculation of the background binding energy distribution for a given miRNA. The background 
energy distribution consists of the probabilities that a particular binding energy is observed. The 
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use of binding energy as a indicative of miRNA binding is a proven method and has been used 
by others (Coronnello et al., 2012; Enright et al., 2003). To compute such distributions, we 
calculate all possible binding energies between every existing k-mer and every miRNA. Only k-
PHUVIRXQGLQWKH¶875RIWKHJHQRPHZHUHXVHGVLQFHWKHFOHDUPDMRULW\RIELQGLQJKDSSHQVLQ
this region. Limiting the k-mers tR WKRVH IRXQG LQ WKH ¶875 UHJLRQ DOVR UHGXFHV WKH
computational time necessary for the computation of the distributions. Counting of all existing k-
mers in the human 3'UTR sequences was done using Jellyfish (Marcais & Kingsford, 2011). It 
has been shown that in most binding events a perfect match of the target sequence with the 
miRNA seed sequence is necessary. This binding characteristic was captured by computing two 
different background distributions for a given miRNA: one for 7-mers seeds and another for 8-
mers seeds. To capture seedless miRNA-target binding, a third distribution that models the 
binding of the entire mature miRNA was computed. In this case, the size of the k-mer is the same 
as the miRNA of interest (Figure 1). Binding energies were calculated using RNAhybrid 
(Rehmsmeier et al., 2004). 
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Figure 1. Algorithm for the computation of binding energy background distribution 
2.2.2 Computation of the log-ratio background distributions 
The second step is the calculation of the background binding energy distribution that assesses 
how likely a SNP will affect binding energy. The computation of these distributions start from 
UDQGRPO\ VDPSOLQJ  NQRZQ 613V WKDW DUH LQ WKH ¶875 RI WKH KXPDQ JHQRPH It is 
important to note that the selection of 50,000 known SNPs was determined after experimenting 
with SNP datasets of various sizes (10000, 20000, 30000, 40000, 50000, 70000 and 100000). 
The 50,000 SNP dataset was selected based on convergence and computational time (in future 
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runs). For every SNP pair two sets of sequences are created: one that contains all possible 
sequences with the reference allele and another set with all possible sequences with the mutant 
allele. The binding energy between every sequence in both sets and a miRNA is calculated. 
Reference and mutated k-mers with the lowest binding energy are kept, and their p-values are 
calculated using the previously calculated background distributions. Finally, a log ratio of the 
binding energy p-values is calculated (Figure 2). This approach is repeated for 7-mer seeds, 8-
mer seeds, and mature miRNAs independently.  
 
Figure 2. Algorithm for the computation of p-value log-ratio background distribution 
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2.2.3 Scoring the effect of a DSV in miRNA binding 
A given DSV is scored for all possible known miRNAs. First, all possible 7-mers that contain the 
DSV being scored are created. These sequences are created based on the genomic region where 
the DSV is found. Therefore, two sets of possible sequences are created: one that contains the 
reference allele and another that contains the mutant allele. Each set contains all possible 
sequences, of the same length, that have the DSV of interest. Energy between all created 
sequences and the miRNA 7-mer seed is calculated. The mutant and reference sequences with 
the lowest binding energy are kept. Using the binding energy background distribution, a p-value 
is calculated for the mutant and reference sequence energies. Here, we assume that a miRNA 
will most likely bind at the position which will confer the most stable conformation, hence the 
lowest binding energy. Next, the log ratio of the two p-values is calculated. The p-value for the 
log ratio is then calculated using the background log ratio distribution. If this value is less than 
0.05, then the SNP is considered to affect miRNA binding and the algorithm stops. If this not the 
case, then the procedure is repeated for 8-mer seed. If the p-value for the scoring of the 8-mer is 
greater than 0.05, then the process is repeated using the entire miRNA length (Figure 3). 
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Figure 3.  is-mirSNP scoring algorithm 
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2.2.4 Validation dataset 
The first step in the evaluation of the performance of our algorithm was the creation of a bona 
fide validation dataset. The validation dataset only contains SNPs that were experimentally 
proven to affect miRNA binding (Adams, Furneaux, & White, 2007; Cheng et al., 2013; Elek et 
al., 2015; Feng et al., 2012; Goda, Murase, Kasezawa, Goda, & Yamakawa-Kobayashi, 2015; 
Landi et al., 2012; S. Y. Lee et al., 2015; Lin et al., 2012; H. Liu et al., 2016; Z. Liu et al., 2011; 
Menard et al., 2016; Nicoloso et al., 2010; Sethupathy et al., 2007; Stegeman et al., 2015; Tang 
et al., 2015; K. Wang et al., 2012; Wynendaele et al., 2010; Xiong et al., 2011; Xu et al., 2013; 
L. Yang et al., 2012; Yousef, 2015; J. Zhang et al., 2014; S. Zhang et al., 2013; Y. Zhang et al., 
2016; Zu et al., 2013). The process of creating this set of miR-SNPs consisted of manually 
curating papers and selecting those that had direct experimental evidence of affecting miRNA 
binding. Computational prediction or indirect evidence of miRNA binding was not accepted, and 
these SNPs were not included in our validation dataset. 
2.2.5 Performance comparison 
Our validation dataset was used to assess the performance of our algorithm as well as other 
existing miRSNP prediction tools. We compared our performance with the following tools: 
MirSNP (C. Liu et al., 2012), PolymiRTS 3.0 (Bhattacharya, Ziebarth, & Cui, 2014), 
mirsnpscore (Thomas et al., 2011) and miRNASNP2 (Gong et al., 2015). The mrSNP tool could 
not be evaluated as its webserver has been offline for the entire time that this paper has been in 
preparation (Deveci et al., 2014). It is also worth noting that according to the mrSNP paper, it 
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has a slightly worse performance than mirSNP, therefore the exclusion of this tool from our 
validation set does not introduce any bias or invalidate our results (Deveci et al., 2014). 
2.3 RESULTS 
2.3.1 Background distributions 
We hypothesized that miRNA-mRNA binding energy for bona fide binding sites is statistically 
significant when compared to a random distribution of binding energies. To test this hypothesis, 
the mRNA-miRNA binding energies for known miRNA binding sites was calculated. The true 
binding sites were obtained from miRTarBase (Chou et al., 2016; Hsu et al., 2011) , and only 
sites validated using direct experimentation were used. Figure 2 shows the binding energy 
distribution with all validated targets for 4 distinct miRNAs: let-7f-5p, miR-98-5p, miR-103a-3p, 
and miR-146a-5p.  Note that miRNA validated targets are in the left-side of the distribution and 
show low binding-energy. The median p-value for the binding energy of 5,369 validated targets 
across 482 human miRNAs is 0.0021. 
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Figure 4. Background energy distributions with known miRNA targets (blue dots) 
2.3.2 Performance and comparison to existing tools 
The creation or destruction of a miRNA binding site by a SNP should alter the miRNA-mRNA 
binding energy. This idea is supported by our previous results that showed the correlation 
between energy and the presence of true binding. Therefore, we implemented and tested our 
miRNA SNP prediction algorithm, called is-mirSNP, using SNPs that are known to affect 
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miRNA binding. We manually curated from the literature a set of 27 experimentally validated 
pairs of miRNA-SNPs known to affect miRNA binding sites. In order to reduce the number of 
false-positives, only miRNA-SNP pairs shown to alter binding sites through direct 
experimentation (luciferase assays, gene-reporter assays) were used. Our algorithm was capable 
of accurately predict the effect of 23/27 miRNA-SNPs pairs (85%) (Table 1). Our algorithm 
performed better than miRSNP, PolymiRTS 3.0, mirsnpscore and miRNASNP2 that were 
capable of accurately predict only 18 (66.6%), 6 (22.2%), 10 (37.03%) and 10 (37.03%) miRNA-
SNP pairs, respectively (Table 1). The miRNA-SNP pairs that our algorithm failed to correctly 
predict, showed minor or no changes in the binding energy between the alleles.  SNP rs7911488 
showed a difference in binding energy between alleles that was not great enough to be 
considered significant by our algorithm. Most the SNPs that were not correctly classified by is-
miRSNP were also missed by all other algorithms. The only exception was SNP rs2240688 
which was correctly classified by miRSNP, mirsnpscore and miRNASNP2. 
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Table 1  Detailed is-rSNP results for DSVs in the validation set. MFE1/2: Minimum Free Energy for allele-1/2; p-value: MFE p-value; LR: log-ratio 
of p-value(1)/p-value(2); p-value(LR): the p-value of the log-ratio (LR).  
RS ID Gene miRNA Prediction Allele1 MFE1 P-value(1) Allele2 MFE2 P-value(2) LR P-value(LR) 
rs5186 AGTR1 has-miR-155-5p 7mer Seed A -8.8 0.027 C -4.5 0.608 3.106 0.000 
rs7911488 BCL2 has-miR-1307-3p miRNA A -23.9 0.024 G -24.5 0.032 0.278 0.097 
rs2239680 BIRC5 has-miR-335-5p 7mer Seed T -9.6 0.010 C -5.5 0.310 3.439 0.001 
rs1434536 BMPR1B has-miR-125b-5p miRNA C -21.5 0.010 T -17.5 0.066 1.908 0.014 
rs7213430 BRIP1 has-miR-101-3p 8mer Seed G -12.1 0.001 A -9.8 0.018 2.858 0.029 
rs2240688 CD133 has-miR-135b-3p miRNA T -16.1 0.261 G -16.1 0.261 0.000 0.584 
rs9341070 ESR1 has-miR-206 7mer Seed C -8.3 0.037 T -6.1 0.312 2.142 0.034 
rs1063320 HLA-G has-miR-148a-3p 7mer Seed C -9.2 0.064 G -11.9 0.005 2.543 0.006 
rs2229295  HNF1B  has-miR-214-5p 7mer Seed G -9.9 0.052 T -13.2 0.003 2.904 0.016 
rs2229295  HNF1B  has-miR-550a-5p 8mer Seed G -13.3 0.012 T -15.2 0.002 1.939 0.039 
rs56109847 HTR3E has-miR-510-5p 7mer Seed G -10.9 0.449 A -5.4 0.704 4.521 0.000 
rs709805 KIAA0182 has-miR-324-3p miRNA G -30.1 0.001 A -25.7 0.007 2.178 0.011 
rs1058205 KLK3 has-miR-3162-5p 7mer Seed C -11.4 0.014 T -12.4 0.003 1.504 0.045 
rs3660 KRT81 has-mir-17-5p 8mer Seed C -11.6 0.011 G -8.9 0.083 2.043 0.010 
rs3660 KRT81 has-mir-20b-5p 8mer Seed C -11.6 0.011 G -8.9 0.083 2.043 0.010 
rs4245739 MDM4 has-miR-191-5p 7mer Seed C -11.2 0.003 A -5.1 0.688 5.458 0.000 
rs12537 MTMR3 has-miR-181a-5p 8mer Seed C -5.7 0.222 T -8.7 0.009 3.184 0.017 
rs3134615 MYCL1 has-miR-1827 7mer Seed C -14.6 0.001 A -10.4 0.049 3.736 0.005 
rs2735383 NBS1 has-miR-629-5p miRNA C -14.9 0.129 G -17.1 0.297 0.837 0.144 
rs6573 RAP1A has-miR-196a-5p 7mer Seed C -7 0.220 A -11 0.004 3.913 0.002 
rs465646 REV3L has-miR-25-3p 7mer Seed G -9.4 0.019 A -7.4 0.159 2.129 0.035 
rs465646 REV3L has-miR-32-5p 7mer Seed G -9.4 0.019 A -7.4 0.159 2.129 0.035 
rs16917496 SET8 has-miR-502-5p miRNA C -16.2 0.259 T -16.2 0.420 0.481 0.233 
rs334348 TGFBR1 has-miR-628-5p miRNA A -20.4 0.001 G -24.6 0.000 3.107 0.003 
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RS ID Gene miRNA Prediction Allele1 MFE1 P-value(1) Allele2 MFE2 P-value(2) LR P-value(LR) 
rs8126 TNFAIP2 miR-184 7mer Seed C -13.6 0.002 T -11.4 0.015 2.118 0.037 
rs1010 VAMP8 miR-370-3p miRNA T -25.6 0.030 C -30.6 0.001 3.101 0.003 
rs9457 WFS1 miR-185-5p 8mer Seed G -10.4 0.015 C -12.7 0.002 2.134 0.026 
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Table 2. Performance comparison of is-miRSNP and other 4 prediction tools. Yes or No values indicates if DSV-miRNA pair was recovered or not 
by the corresponding algorithm.  
 
RS ID miRNA is-mirSNP miRSNP PolymiRTS mirsnpscore miRNASNP2 References 
rs5186 miR-155-5p Yes Yes Yes No No (Sethupathy et al., 2007) 
rs7911488 miR-1307-3p No No No No No (Tang et al., 2015) 
rs2239680 miR-335-5p Yes Yes No Yes Yes (Zu et al., 2013) 
rs1434536 miR-125b-5p Yes Yes No Yes No (Feng et al., 2012) 
rs7213430 miR-101-3p Yes Yes No Yes No (H. Liu et al., 2016) 
rs2240688 miR-135b-3p No Yes No Yes Yes (Cheng et al., 2013) 
rs9341070 miR-206 Yes No No No No (Adams et al., 2007) 
rs1063320 miR-148a-3p Yes Yes No Yes Yes (Menard et al., 2016) 
rs2229295 miR-214-5p Yes Yes No No Yes (Goda et al., 2015) 
rs2229295 miR-550a-5p Yes Yes No No Yes (Goda et al., 2015) 
rs56109847 miR-510-5p Yes Yes No No No (Y. Zhang et al., 2016) 
rs709805 miR-324-3p Yes No No No No (Landi et al., 2012) 
rs1058205 miR-3162-5p Yes Yes Yes Yes Yes (Yousef, 2015) 
rs3660 mir-17-5p Yes Yes Yes Yes Yes (S. Y. Lee et al., 2015) 
rs3660 mir-20b-5p Yes Yes Yes Yes Yes (S. Y. Lee et al., 2015) 
rs4245739 miR-191-5p Yes Yes No Yes Yes (Wynendaele et al., 2010) 
rs12537 miR-181a-5p Yes Yes No No Yes (Lin et al., 2012) 
rs3134615 miR-1827 Yes Yes No Yes No (Xiong et al., 2011) 
rs2735383 miR-629-5p No No No No No (L. Yang et al., 2012) 
rs6573 miR-196a-5p Yes No No Yes No (K. Wang et al., 2012) 
rs465646 miR-25-3p Yes Yes No No No (S. Zhang et al., 2013) 
rs465646 miR-32-5p Yes Yes No No No (S. Zhang et al., 2013) 
rs16917496 miR-502-5p No No No No No (Xu et al., 2013) 
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RS ID miRNA is-mirSNP miRSNP PolymiRTS mirsnpscore miRNASNP2 References 
rs334348 miR-628-5p Yes No No No No (Nicoloso et al., 2010) 
rs8126 miR-184 Yes Yes Yes No Yes (Z. Liu et al., 2011; J. Zhang et al., 2014) 
rs1010 miR-370-3p Yes No No No No (Stegeman et al., 2015) 
rs9457 miR-185-5p Yes No Yes No No (Elek et al., 2015) 
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2.3.3 Discussion 
We developed a new algorithm, is-miRSNP, that can accurately predict the effect of a SNP on a 
miRNA binding site. Our tool addresses several issues that are not covered by existing tools. 
First, is-mirSNP can be easily deployed as a standalone software or be integrated into existing 
pipelines. It also can predict the effect of existing and novel SNPs. We also addressed the issue 
of variant prioritization by associating the difference and strength of miRNA binding sites with 
p-values, concepts which most researchers and scientists are familiar with.  
The performance of is-mirSNP was compared with other tools, using a set of 27 
experimentally validated miRNA-SNP pairs. To reduce bias and remove false-positives, we 
manually curated the literature and selected only miRNA-SNP pairs that were experimentally 
validated by direct experimentation. Is-miRSNP could correctly recover the highest number of 
validated miRNA-SNP pairs (85%). The second best-performing tool mirSNP, could recover 
66.6% of all validated miRNA-SNP pairs, which agrees with the 70% recovery rate reported by 
another study (Deveci et al., 2014). Only one SNP-miRNA (rs2240688 and miR-135b-3p) pair 
was not predicted by our algorithm, and was accurately classified by miRSNP, mirsnpscore and 
miRNASNP2. Our tool only accounts for changes in binding energy between alleles. Therefore, 
SNPs that alters other binding features (i.e. miRNA-mRNA structure, conservation), but not 
energy will not be accurately classified by is-miRSNP. If there is a difference in binding energy 
between alleles but the difference is not statistically significant, then the SNP-PL51$SDLUZRQ¶W
be considered to alter binding. This is the case of SNP-miRNA pairs: rs7911488, miR-1307-3p; 
rs2735383, miR-629-5p. According to Yang et. al., SNP rs2735383 alters the binding of the pre-
mir form of miR-629-5p, but the mature form was never tested for binding. Is-miRSNP and the 
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other tools described here were designed to evaluate the binding of mature miRNAs, therefore it 
is expected that none of the methods will accurately predict the effect of SNP-non-mature 
miRNA pairs.  
Unfortunately, we could not assess the rate of false positives predicted by these tools due 
to a lack of data. It is widely known that the medical literature is biased towards positive results 
and rarely reports failed experiments (Dickersin, Chan, Chalmers, Sacks, & Smith, 1987).  Next, 
we will add to our algorithm the capability of predicting the effect of insertion-deletions 
(INDEL) and pre-miRNAs. 
In summary, we have presented a new tool called is-miRSNP which shows better 
performance than existing methods, and addresses most of the weakness present in such tools.
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3.0  PIPELINE FOR PRIORITIZATION AND FUNCTIONAL EVALUATION OF 
DNA SEQUENCE VARIANTS 
3.1 BACKGROUND 
Transcriptome studies became popular with the invention of microarray technologies, which 
allowed scientists to interrogate the entire genome at a low cost. Despite their affordability, 
microarrays have three main limitations: probe design requires a priori sequence information or 
whole genome information, cross-hybridization between similar sequences, and poor 
quantification of lowly and highly expressed genes (Hrdlickova, Toloue, & Tian, 2017; Kukurba 
& Montgomery, 2015).  
RNA sequencing (RNA-Seq) through high-throughput NGS has revolutionized our 
understanding of the transcriptome and is now the method of choice for the study of gene 
expression. RNA-Seq is a much more powerful technology and does not suffer from the same 
limitations as microarray, it has less background noise and a greater dynamic detection range. 
RNA-Seq provides a quantitative view of gene expression, alternative splicing and allele-specific 
expression. It also directly reveals the sequence identity essential for the discovery of new 
transcripts and isoforms (Hrdlickova et al., 2017; Kukurba & Montgomery, 2015). 
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Knowledge about gene expression plays an important role in deciphering the underlying 
biology of diseases, however understanding the genetic variation causing expression changes is 
also paramount. The advent of microarrays and NGS technology has also revolutionized the field 
of GWAS, making it more affordable and common, thus being responsible for the sharp increase 
in the number of published and publicly-available GWAS datasets observed in recent years. The 
main goal of GWAS has been to identify genetic risk factors that can be used to uncover genetic 
clues about cellular and molecular pathways possibly leading to new prevention strategies and 
treatments (Bush & Moore, 2012). An important concept in GWAS data analysis and results 
interpretation is the one of linkage disequilibrium (LD). LD is a measure of the linkage between 
two markers. It expresses how the allele of one SNP is correlated or inherited with an allele of 
another SNP within a population. LD values are most commonly reported in terms of the 
statistical measure of correlation r2 (value between 0 and 1). LD is calculated between two SNPs, 
and high r2 values mean that two SNPs are linked. If two SNPs are in LD (high r2 value), it 
means one allele of the first SNP is usually observed with one allele of the second SNP (Bush & 
Moore, 2012). 
In recent years, we have seen an explosion in the amount of genomic data available. This 
excess of data has also created the need for new bioinformatics pipelines and methods capable of 
analyzing, interpreting and integrating genomic data. This chapter describes a new pipeline 
capable of analyzing RNA-Seq data, integrating its results with available GWAS using an LD-
based approach, and functionally annotating DSVs associated with the phenotype being studied.  
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3.2 METHODS 
This section describes, in detail, the pipeline for prioritization and functional evaluation of DSVs 
(Figure 5). The pipeline has four main sections: 1) analysis of RNA-Seq datasets, 2) 
identification of variants based on RNA-Seq data, 3) GWAS data analysis, and 4) functional 
annotation of DSVs. 
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Figure 5. Pipeline for functional annotation of DSVs obtained from RNA-Seq and GWAS datasets 
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3.2.1 RNA-Seq analysis 
Analysis of RNA-Seq data from raw FASTQ files consists of 5 main steps: 1) data quality-
control, 2) adapter trimming, and read filtering and trimming; 3) read mapping; 4) estimation of 
gene and isoform expression; 5) differential gene expression analysis. 
3.2.1.1  Data quality-control 
The first step of the RNA-Seq analysis pipeline consists of assessing the quality of the raw data. 
This is an important step in the analysis pipeline as poor-quality data will likely lead to erroneous 
results. Several metrics should be calculated to assess RNA-Seq data quality, including: base 
sequence quality, base sequence content, reads GC content, number of missing calls, sequence 
length distribution, sequence duplication levels. In this pipeline the FastQC software (Andrews, 
2012), is used to calculate and display data quality metrics.  
3.2.1.2 Adapter trimming and read filtering and trimming 
Adapter trimming, and read filtering and trimming are steps in the pipeline that directly depend 
on the library preparation method, and results from previous step. Adapter sequences can be 
present or not depending if they were added and/or removed during library preparation stage. If 
present they need to be removed, as they will affect read mapping and expression estimation. For 
the same reasons, low-quality reads should also be removed. Often, NGS reads will have low-
TXDOLW\EDVHVDWWKH¶¶RUERWK ends. In such cases, read trimming is preferred to read filtering, 
since it maximizes data utilization as it preserves good quality-bases in the middle of the 
sequences. For the pipeline described here, Cutadapt (Martin, 2011) is used for adapter 
trimming, and read filtering and trimming.  
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3.2.1.3 Read mapping 
The third step in the RNA-Seq analysis pipeline is read mapping. Reads need to be mapped to 
the genome before gene expression can be estimated. Several algorithms were recently 
developed to accomplish this task. We used Bowtie (Langmead, Trapnell, Pop, & Salzberg, 
2009), an ultrafast, memory-efficient algorithm that uses Burrows-Wheeler indexing. Bowtie can 
accurately map an RNA-Seq sample to the human transcriptome in only a couple of hours. After 
read mapping is completed, the generated BAM files need to be evaluated for quality-control 
purposes. Metrics like number and percentage of mapped reads should be calculated to determine 
whether the data was appropriately mapped. 
3.2.1.4 Estimation of gene and isoform expression  
After read mapping, gene and isoform expression are ready to be estimated. This is a difficult 
problem since mapped reads do not always map to unique positions in the genome, making it 
hard to distinguish which gene and/or isoform the target sequence originated from. In this 
pipeline, we utilize the RSEM algorithm to estimate gene and isoform abundance. RSEM 
implements a quantification method for expression that uses the expectation maximization to 
accurately estimate read mapping uncertainty (Li & Dewey, 2011). 
3.2.1.5 Differential gene expression analysis 
The most common goals of RNA-Seq experiments are: 1) to understand the differences in the 
transcriptome between two cell types, 2) to identify transcriptional differences between health 
and disease states, and 3) investigate gene expression changes caused by interventions and drugs. 
Therefore, an important step in an RNA-Seq pipeline is to find differentially expressed genes and 
isoforms between two or more groups. Statistical tests designed for microarray data cannot be 
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applied to RNA-Seq data. This is mainly because the distribution of RNA-Seq data follows a 
negative binomial distribution, and cannot be properly analyzed by methods that assume 
normality. Therefore, to perform differential expression analysis, a method that takes into 
consideration the negative binomial distribution needs to be used. Recently, several algorithms 
like EBSeq (Leng et al., 2013), DESeq (Love, Huber, & Anders, 2014), Limma-Voom (Ritchie 
et al., 2015) and EdgeR (McCarthy, Chen, & Smyth, 2012) have been developed. In the present 
pipeline, we utilize EdgeR, which implements a negative binomial regression model that can 
accurately identify differentially expressed genes. EdgeR is a fast algorithm that can handle large 
datasets, and it is flexible enough to take into consideration various experimental designs. 
3.2.2 Variant identification from RNA-Seq 
Once RNA-Seq analysis is completed, the next step in the pipeline is to identify variants related 
to the genes of interest. In the proposed pipeline, these are the set of differentially expressed 
genes. It is worth noting that if a user does not have control samples, or is not interested in 
comparing multiple groups and/or treatments, differentially expressed genes can be replaced by 
any set of genes (i.e. genes inside biologically meaningful pathways, or genes with high or low 
expression). Variants are identified by intersecting the genomic coordinates of the differentially 
expressed genes and their flanking regions (5kb upstream and downstream of the gene) with a 
genetic variant database like dbSNP (Sherry et al., 2001).  
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3.2.3 GWAS data analysis 
The previous step will result in a variant set that is only a fraction of the total number of variants 
in the human genome. However, it is likely that the number of variants will still be too large, and 
will include many DSVs that have no biological function. The sheer number of DSVs also make 
manual curation and interpretation of variants virtually impossible. To further reduce the number 
of variants, our pipeline utilizes results obtained from GWAS datasets. First, tag-SNPs or 
variants that are strongly associated with the condition being studied are obtained from available 
GWAS data. Next, LD is calculated between GWAS variants and variants located within 5kb to 
either side of differentially expressed genes. LD analysis is computed using the software PLINK 
(Purcell et al., 2007). The population data and haplotypes needed for LD calculations are 
obtained from whole-genome sequencing projects such as the 1000 Genomes Project (Genomes 
Project et al., 2010). The set of variants in strong LD (R2 t 0.8) with GWAS variants are 
considered strongly associated with the condition being studied, and are next functionally 
annotated.  
3.2.4 Functional Annotation of DSVs 
The first step in predicting DSV function is annotation. It provides detailed information about the 
YDULDQWV VXFKDV  JHQRPLF UHJLRQ ¶875¶875XSVWUHDPGRZQVWUHDP H[RQ LQWURQ 
gene; 3) functional characterization of exonic (synonymous, non-synonymous, stop-gain) and 
splice-site variants. In this stage of the pipeline all variants in strong LD with Tag-SNPs are 
annotated, and grouped by genomic region (i.e. XSVWUHDP ¶875 H[RQ LQWURQ ¶875 DQG
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downstream). DSVs are annotated using ANNOVAR (K. Wang, Li, & Hakonarson, 2010; H. 
Yang & Wang, 2015).  
3.2.4.1 Functional annotation of exonic and splicing DSVs 
The effects of non-synonymous DSVs are predicted using the CAROL algorithm (Lopes et al., 
2012). CAROL combines the scores of the two most commonly used tools for predicting the 
effect of non-synonymous variants, namely PolyPhen (Adzhubei et al., 2010) and SIFT (Kumar, 
Henikoff, & Ng, 2009). Both algorithms use conservation and evolutionary patterns to predict 
whether a variant is deleterious or not. SIFT determines the effect of a variant by calculating the 
probability of an amino-acid change at all positions across a set of multiple aligned homologous 
sequences. PolyPhen predicts whether a variant is potentially harmful by calculating the 
posterior probability that the DSV is deleterious. PolyPhen also considers the changes in the 
protein 3D structure in its predictions. Often the predictions by PolyPhen and SIFT will not agree 
and/or will be hard to interpret. We solved this problem in our pipeline by using CAROL, which 
utilizes a weighted Z method to derive a SIFT-PolyPhen combined scored. CAROL not only 
solves the ambiguity of prediction between SIFT and PolyPhen, but it also has increased 
predictive power and accuracy when compared to these tools alone (Lopes et al., 2012). SIFT 
and PolyPhen scores as well as variants in splice-sites are obtained from ANNOVAR. 
3.2.4.2 )XQFWLRQDODQQRWDWLRQRI¶875'69V 
7KH LPSDFW RI ¶875 '69V RQ PL51$ ELQGLQJ VLWHV LV SUHGLFWHG XVLQJ WKH LV-miRSNP 
algorithm (described in detail on Chapter 2). 
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3.2.4.3 )XQFWLRQDODQQRWDWLRQRILQWURQLFSURPRWHUVDQG¶875'69V 
,QWURQLFSURPRWHUDQG¶875'69VDUHWHVWHGIRUWKHLUSRWHQWLDOHIIHFWRQ7)ELQGLQJVLWHVThe 
effects of these variants on TF binding are predicted by using the BayesPI-BAR algorithm (J. 
Wang & Batmanov, 2015). The BayesPI-BAR algorithm utilizes a Bayesian approach to 
estimate the changes in the binding affinity of TF caused by a genetic variant. The method 
incorporates TF chemical potentials and putative direct protein-DNA interactions not considered 
by other methods (J. Wang & Batmanov, 2015). 
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4.1 BACKGROUND 
Idiopathic inflammatory bowel disease (IBD) is a group of chronic, relapsing and remitting 
JDVWURLQWHVWLQDO WUDFW GLVRUGHUV WKDW LQFOXGH WZR FRPPRQ VXEW\SHV &URKQ¶V GLVHDVH &' DQG
ulcerative colitis (UC).  Research over the last few decades has led to a general consensus that 
IBD pathogenesis involves complex interactions between host genetic factors, environmental 
triggers, and the gut microbiota (Ananthakrishnan, 2015; Fonseca-Camarillo & Yamamoto-
Furusho, 2015; Podolsky, 2002). The genetic contribution to IBD was investigated by a GWAS 
and GWAS follow-up study involving more than 75,000 cases and controls (Jostins et al., 2012). 
This study, together with more recent genetic mapping studies in IBD, have identified 241 IBD-
associated loci spanning 1,540 genes (de Lange et al., 2017; Jostins et al., 2012). Interestingly, 
for most of these IBD-associated loci, the SNP(s) with the strongest association signal(s) lie 
outside known genes in non-coding regions of the genome, where they are presumed to play a 
role in regulation of gene expression.  This is a theme that has been observed in GWAS of many 
complex human diseases (Hindorff et al., 2009). 
 
      4.0 ANALYSIS OF INFLAMMATORY BOWEL DISEASE DATASET
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IBD are chronic, immune-mediated diseases characterized by persistent inflammation of 
the bowel. Chronic inflammation is thought to be due to an exacerbated immune response 
against commensal enteric organisms in a genetically predisposed host (Fonseca-Camarillo & 
Yamamoto-Furusho, 2015; Sartor, 2006). Production of proinflammatory cytokines and 
chemokines is increased in IBD, which ultimately leads to the abnormal activation of immune 
cells. Naïve CD4+ T cells have a crucial role in the initiation of the immune response by 
activating, expanding and differentiating into effector cells. Two important effector cell types, 
derived from naive CD4+ T cells, are Th1 and Th2. Each of these T effector cell types has a 
particular role in inflammation and secretes specific cytokines (Z. J. Liu, Yadav, Su, Wang, & 
Fei, 2009). Th1 cells are thought to be involved in CD, while Th2 cells are mostly observed in 
UC (Geremia, Biancheri, Allan, Corazza, & Di Sabatino, 2014; Z. J. Liu et al., 2009).  High 
levels of IL17-A, a cytokine produced by a third type of effector T-cell named Th17, has been 
detected in both UC and CD samples (Z. J. Liu et al., 2009). Immunohistochemistry of these 
samples revealed enrichment for CD-68+ cells that express IL-17.  Furthermore, recent data 
suggest that Th17 cells may play an important function in the immune response against 
extracellular pathogens. Th17 cells might be responsible for clearing pathogens that are not 
effectively dealt with by Th1 and Th2. Moreover, studies have shown that Th17 are important 
for the immune response modulation in various other auto-immune diseases like psoriasis and 
rheumatoid arthritis (Adamik et al., 2013; Z. J. Liu et al., 2009). 
The maturation of naïve CD4+ T cells into Th17 cells requires a special environment. 
Studies have shown that IL-1ȕDQG ,/-23 are required for the differentiation and expansion of 
Th17 cells (Z. J. Liu et al., 2009). Another important molecule, prostaglandin E2 (PGE2), also 
seems to be also involved in the regulation of Th17 cells. PGE2 exhibits both anti-inflammatory 
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and pro-inflammatory properties. In the presence of IL-23, IL-1ȕ and PGE2, Th17 cells seem to 
be insensitive to the anti-inflammatory, yet still sensitive to the pro-inflammatory properties of 
PGE2 (Barrie et al., 2011). IL-17A and IL-17F are cytokines produced by Th17 cells and are 
directly linked to the pathogenesis of IBD (Adamik et al., 2013; Barrie et al., 2011). The 
presence of IL-23 and IL-1B preferentially induce the expression of IL-17F. The addition of 
PGE2 to IL-23 and IL-1B treatments induce the expression of IL-17A by CD4+ T cells via the 
PGE2 EP4 receptor. Therefore, the presence of PGE2 shifts the balance of IL-17F mediated 
immune response to a predominantly IL-17A response. In certain mouse models, IL17-A seems 
to protect against IBD onset, whereas IL-17F has the opposite effect (Adamik et al., 2013). 
Despite the evidence that Th17 cells play an important role in IBD, their mechanism of 
action is not well understood, and only a few works have studied the effects of PGE2 on Th17-
enriched cell populations (Adamik et al., 2013; Barrie et al., 2011; Z. J. Liu et al., 2009). In 
addition to Th17 modulation, IL-23, IL-1ȕ and PGE2 have been shown to be directly involved in 
IBD, as each of these molecules have receptor encoded by genes (IL23R, IL1R1 nad PTGR4) 
implicated in IBD GWAS studies (Jostins et al., 2012; Lees, Barrett, Parkes, & Satsangi, 2011; 
Uniken Venema, Voskuil, Dijkstra, Weersma, & Festen, 2017).  
The purpose of this work is to study the mechanisms by which PGE2 affects gene 
expression of activated, IL-23 and IL-ȕ-treated, effector memory T cells. Gene expression 
analyses were also linked to GWAS data in order to identify DNA sequence variants (DSVs) that 
can potentially modulate Th17 function and might be of importance to IBD pathology. 
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4.2 METHODS 
4.2.1 Cell isolation, purification and stimulation 
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on 
Ficoll-based Lymphocyte Separation Medium (MP Biochemicals) from eight anonymous healthy 
adult human leukopaks obtained from the Pittsburgh Central Blood Bank as approved by the 
University of Pittsburgh IRB. CD4+CD45RO+CD197- T cells were enriched by negative 
selection from PBMCs using the human CD4+ Effector Memory T Cell Isolation Kit (Miltenyi 
Biotec). Cell purity was assessed by flow cytometry via staining for CD4 and CD45RO surface 
expression. Isolated T cells were cultured at 1×10-6 cells/mL in X-VIVO-20 medium (Lonza 
BioWhittaker) supplemented with T cell activation beads (Miltenyi Biotec) coated with anti-
CD2/-CD3/-CD28 antibodies (1 bead per 5 cells). The cells were treated with the T cell 
activation beads (ActivBeads) alone or in combination with either IL-23+IL-ȕQJP/HDFK
ERWKIURP5	'6\VWHPV3*(ȝ06LJPD-Aldrich Chemical); or IL-23+IL-ȕ3*(7KH
cell cultures were incubated at 37°C, 5% CO2, for 6 hours because preliminary time course 
studies using cells from three donors showed that IL17A mRNA expression increased within 3 
hours, peaked at 6 hours, and subsequently declined over the next 18 hours following treatment 
with T cell activation beads alone. The cells were then harvested and lysed with Qiazol reagent, 
and total RNA was extracted using the miRNeasy Mini Kit (Qiagen). 
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4.2.2 RNA sequencing 
A total of 32 RNA samples (from four cell culture conditions for each of eight human cell 
donors) were converted to cDNA using the Ovation® RNA Amplification System V2 (NuGEN) 
IROORZLQJWKHPDQXIDFWXUHU¶VUHFRPPHQGHGSURWRFRO7KHF'1$SURGXFHGE\WKLVNLWZDVWKHQ
sheared to an average size of 250 bp using a Covaris E220 acoustic wave system following 
PDQXIDFWXUHU¶VUHFRPPHQGHGSURWRFRO7KHVKHDUHG'1$ZDVSUHSDUHGIRU,OOXPLQD6HTXHQFLQJ
using the TruSeq v2 kit for library preparation with barcode adaptors AD001-016, AD018-022, 
AD023, AD025, and AD027. The libraries were pooled in groups of eight and amplified, 
quantified by qPCR on a Life Technologies Gene Amp® 9700 RT- PCR device, and diluted to a 
concentration of 11 pM for deposition and clustering on an Illumina Flowcell using the Illumina 
cBot. The DNA was striped across 2 wells each of the flowcell. The DNA was then sequenced 
on an Illumina HiSeq 2000 using the Illumina SBS kit v3, 200 cycle, paired end chemistry. The 
output was de-multiplexed and base calls were converted to fastq format using CASAVA v1.8.2. 
4.2.3 Analysis of gene expression 
The RSEM algorithm (Li & Dewey, 2011) was used with the default parameters to map the 
sequencing reads on the human genome (version hg19) and estimate gene and isoform 
expression. Differentially expressed genes and isoforms were identified using edgeR (McCarthy 
et al., 2012). Since the analyzed samples were derived from eight individuals and four culture 
conditions each (T cell activation beads (ActivBeads) alone or in combination with either IL-
23+IL-ȕ, PGE2 or IL-23+IL-ȕ3*(), we used edgeR with WKH³EORFNLQJ´IHDWXUHWRaccount 
for the same donor samples. The threshold for differential gene expression was set to FDR<0.05 
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in all comparisons. Additional statistical analyses were done with in-house made scripts in R. 
Pathway analysis of differentially expressed genes was done using IPA (Ingenuity® Systems, 
www.ingenuity.com). 
4.2.4 Evaluation of cis effects of IBD-associated SNPs within differentially expressed gene 
regions 
Gene models and exon boundaries were obtained from the UCSC Genome Browser (hg19) 
(Karolchik et al., 2004). SNPs localized within IBD loci of the differentially expressed genes in 
IBD-associated genomic regions were retrieved from dbSNP version 147 (Sherry et al., 2001) 
and annotated using ANNOVAR (K. Wang et al., 2010; H. Yang & Wang, 2015). 
For completeness, we also ranked the non-synonymous SNPs using CAROL (Lopes et 
al., 2012) a program that calculates how likely a particular variant impacts protein structure and 
function. CAROL score is based on Polyphen (Adzhubei et al., 2010) and Sift (Kumar et al., 
2009) which were obtained from ANNOVAR. SNPs inside introns and regulatory regions 
(upstream, downstream¶875) were evaluated using the BayesPI-BAR algorithm (J. Wang & 
Batmanov, 2015) for the transcription factors that had at least 5 reads in each of the samples and 
treatments. SNPs in WKH ¶ XQWUDQVODWHG UHJLRQV ¶875 ZHUH HYDOXDWHG IRU their potential 
influence on miRNA binding using MirSNP (C. Liu et al., 2012). Also, SNPs that alter splice 
sites were reported.  
For each one of the IBD-associated regions, Jostins et al. (Jostins et al., 2012) and 
DeLange et al. (de Lange et al., 2017) identified one SNP that could best explain the GWAS 
signal. LD analysis of these tag-SNPs, and SNPs previously identified as functionally important 
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by our analyses was performed using PLINK (Purcell et al., 2007). LD analysis was done using 
haplotypes for all individuals of European ancestry listed in the 1000 Genomes Project phase 3.  
4.3 RESULTS 
4.3.1 The effects of PGE2 dominate the differential gene expression observed in activated 
effector memory T cells treated with IL-23+IL-ȕ3*( or all three mediators 
In the all-groups comparison (edgeR, ANOVA-like test) we identified a total of 3,541 genes as 
differentially expressed between at least one of the groups (FDR < 0.05) (Table 3). 
Unsupervised hierarchical bi-clustering showed two major groups of samples: PGE2-induced 
cells and non-PGE2-induced cells (Figure 6). In addition, one or more isoforms of 1,122 genes 
were differentially expressed in an all group comparison (total number of differentially expressed 
isoforms = 1,349; Table 4) 
Table 3. Summary table of differentially expressed genes  
COMPARISON 
NUMBER OF 
SIGNIFICANT 
GENES (FDR < 
0.05) 
NUMBER OF 
SIGNIFICANT 
GENES IN IBD-
ASSOCIATED 
REGIONS (FDR < 
0.05) 
NUMBER OF NON-
SIGNIFICANT 
GENES 
all groups' comparison 3541 326 17106 
Control+IL23.IL1B 
vs 
IL23.IL1B.PGE2+PGE2 
3562 336 17085 
IL23.IL1B.PGE2 
vs 
IL23.IL1B 
2472 241 18175 
IL23.IL1B 
vs 
Control 
159 17 20488 
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Figure 6. Hierarchical bi-cluster of differentially expressed genes across all stimuli (ANOVA-like 
test). High expression values are in red and low expression values  are in green.  
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Table 4. Summary table of differentially expressed isoforms 
COMPARISON 
NUMBER OF 
SIGNIFICANT 
ISOFORMS (FDR < 
0.05) 
NUMBER OF 
SIGNIFICANT 
ISOFORMS IN IBD-
ASSOCIATED 
REGIONS (FDR < 
0.05) 
NUMBER OF NON-
SIGNIFICANT 
ISOFORMS 
all groups' comparison 1349 184 55306 
Control+IL23.IL1B 
vs 
IL23.IL1B.PGE2+PGE2 
1859 236 54796 
IL23.IL1B.PGE2 
vs 
IL23.IL1B 
637 85 56018 
IL23.IL1B 
vs 
Control 
65 7 56590 
 
 
4.3.2 Effect of PGE2 on the transcriptome of activated effector memory T cells 
We found 3,562 differentially expressed genes in effector memory T cells treated with PGE2 vs 
without PGE2 (Table 3). In general, samples from the same donor are clustered together within 
each of the two largest groups (Figure 7), despite using the patient_ID as group variable 
(blocking) during the analysis. Exceptions are samples #2 and #6 in the non-PGE2 treated cells 
and #7 and #8 in the PGE2 treated cells. A significant number of differentially expressed genes 
(336 of the 3,562 genes) belong to the group of 1,540 genes that are located within IBD loci 
)LVKHU¶VH[DFWWHVWp-value=e-6).  
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Figure 7. Hierarchical bicluster of DE genes between ActivBeads+IL23+IL1ȕ vs 
ActivBeads+IL23+IL1ȕ+PGE2 stimuli across all samples. High expression values are in red and low expression 
values  are in green. 
4.3.3 Effects of IL-23 and IL-ȕ on the transcriptome of activated effector memory T cells 
We also looked at the gene expression differences induced by IL23+IL1ȕ, and we found their 
effects to be relatively small. A total of 159 genes were differentially expressed as a result of 
IL23+IL1ȕ stimulation (Table 3), and 17 of them belong to IBD regions.  
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4.3.4 Pathway analysis reveals important relationships to IBD 
Ingenuity Pathway analysis revealed several networks with statistically overrepresented 
differentially expressed genes in these categories. In particular, we found that the 2,472 
differentially expressed genes between samples activated with ActivBeads+IL23+IL1ȕ+PGE2 vs 
ActivBeads+IL23+IL1ȕ are overrepresented in 25 networks. Similarly, the differentially 
expressed genes in samples activated with ActivBeads+IL23+IL1ȕ vs ActivBeads alone were 
overrepresented in two networks (p-value  0.001). Figure 8 presents four networks from the 
ActivBeads+IL23+IL1ȕ vs ActivBeads+IL23+IL1ȕ+PGE2 comparison that are particularly 
interesting because they include several up- or down-regulated genes inside IBD-associated 
regions, suggesting relevance to IBD. These networks are related to the function and 
development of the immune response. Genes such as IL2, IL7R, CREM and FOS that are 
immune system response genes and located within IBD-associated regions were found in the 
networks.  
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Figure 8. Networks of differentially expressed genes ActivBeads+IL23+IL1ȕ vs 
ActivBeads+IL23+IL1ȕ+PGE2. Blue asterisks indicated genes located inside IBD-associated regions. P-value 
FDOFXODWHGE\WKH)LVKHU¶VH[DFWWHVW is indicative of how overrepresented the differentially expressed genes are in 
the given network.  
4.3.5 SNPs with potential functional role in IBD 
Jostins et al. (Jostins et al., 2012) and DeLange et al. (de Lange et al., 2017) identified 241 IBD-
associated genomic regions that contain 1,540 genes. 326 of these genes are in the group of 
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3,541 differentially expressed between one or more of the four treatments (p-value=e-5 Fisher's 
exact test). (Table 3). They include several genes related to immune responses such as TNF, 
IFN-Ȗ, IL7R, IL2, IL21. When we compared gene expression differences between ,/,/ȕ
versus ,/,/ȕ3*( stimulation, we found a total of 2472 differentially expressed genes, 
241 of which are in IBD-associated regions (p-value=1e-6 Fisher's exact test). We selected and 
further analyzed SNPs located within 5kb upstream and downstream of these 241 genes. We 
found a total of 582,510 SNPs in these regions, with most of them being intronic (478,013 or 
~82%) (Table 5). We assessed the functional role of (i) non-synonymous SNPs in altering 
protein folding and function; (ii) 613VLQ¶-UTR in altering miRNA binding; and (iii) promoter, 
¶-UTR and intronic SNPs in altering the binding sites of known transcription factors. A total of 
23,809 non-synonymous exonic SNPs, belonging to 333 of these genes, were predicted to be 
deleterious.  From all 23,809 non-synonymous SNPs predicted to be deleterious, 6 of them were 
inside DE genes and in strong LD with IBD-tag SNPs (Table 6).  
A total of 4,460 SNPs found in WKH¶87R, intronic, upstream and downstream regions of 
241 genes in the IBD regions were predicted to disrupt TF binding and were in strong LD with 
IBD-tag SNPs. Some of those SNPs are predicted to disrupt binding sites for TFs located in the 
IBD regions, like BACH2 (promoters of ADAM30, JAK2 and introns of CREM, SMAD3, 
STAT3), CEBPB (promoters of IRGM, USP1), SMAD3 (promoter of CREM) among others. 
Table 7 presents 34 of these SNPs that are located upstream or downstream of differentially 
expressed genes. This list includes 13 SNPs in the promoter regions of important immune related 
genes like CREM, IL8R1, JAK2 and MAP3K8.  
We identified 71 SNPs located in tKH¶875UHJLRQVRI DE genes in IBD loci that are 
in strong LD with IBD-tag SNPs and are predicted to change the binding of miRNAs. These are 
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predicted to alter the binding of a total of 23 different miRNAs (Table 8). We found 18 SNPs in 
¶875 UHJLRQV RI '( JHQHV WKDW DUH LQ VWURQJ /' ZLWK ,%'-tag SNPs (Table 8). Linkage 
GLVHTXLOLEULXP DQG IXQFWLRQDO SUHGLFWLRQ VKRZHG WKDW WKH WDJ 613 UV ORFDWHG RQ WKH ¶
UTR of the CD226 gene is predicted to alter miR-181a-5p and miR-502-5p binding (Table 8). 
Finally, splice site analysis identified 5 SNPs that changes splice sites and are in linkage 
disequilibrium with IBD tag-SNPs, however these are not in differentially expressed genes 
(Table 9). 
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Table 5. Summary of DE genes between IL23+IL1β vs. IL23+IL1β +PGE2 and the number of DSVs found within and around these genes. 
FPKM: fragment per kilobase per million.  
GENE MEAN.FPKM values in different stimuli # of SNPs with respect to gene's location 
 STIM (Ctrl) IL23+IL1β PGE2 IL23+IL1β +PGE2 upstream 5-UTR exonic intronic 3-UTR downstream 
ACSL6 6.3575 6.8375 3.30125 3.3475 46 46 342 2588 140 47 
ACYP1 5.6625 4.17375 6.5625 6.5175 0 23 53 592 18 23 
ADK 12.90125 13.98 18.71 20.785 0 10 5 348 0 0 
ADO 7.55875 10.655 5.93625 5.4825 38 23 148 0 125 51 
ANKRD33B 1.41375 1.9525 0.9325 1.35125 48 4 139 4327 394 39 
ANXA6 9.8375 8.855 7.2675 6.73 43 38 362 2878 48 48 
APOBEC3C 18.525 15.98 11.55875 11.2725 71 14 104 260 36 55 
APOBEC3G 25.45 25.0825 14.9575 17.47375 44 19 216 579 24 50 
ATF6B 13.7 11.74625 15.9425 14.53375 0 7 311 602 28 30 
ATP1B1 2.05875 2.05625 3.05375 3.41 0 0 84 480 55 0 
ATP6V1F 13.485 10.55 11.03 14.805 33 16 75 117 11 0 
ATXN2L 45.165 46.67875 38.60625 36.10625 36 18 603 860 89 51 
BACH2 35.60125 33.2425 58.6925 55.79 32 46 26 12616 0 0 
BCL9L 7.77875 7.13 6.50375 5.64 4 40 854 419 128 0 
BORCS5 2.05 1.9025 3.3925 3.21625 0 44 110 5346 77 52 
C6orf48 78.2425 68.72 79.99375 96.265 11 81 51 239 17 45 
C6orf99 0 0 0.14625 0.4575 42 47 22 1858 8 44 
CACNA1I 0.4175 0.31 0.41375 0.52125 47 0 37 153 0 0 
CAMSAP2 5.105 6.1075 5.12875 4.495 39 13 546 4809 86 44 
CBLL1 22.15625 23.2075 19.3475 17.9325 61 42 218 642 119 43 
CBX7 4.60875 4.01375 5.2375 5.055 37 4 120 908 167 64 
CCDC86 9.34125 10.4525 6.45875 7.095 44 23 213 385 35 0 
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CCR2 8.36375 7.825 12.68875 12.65625 46 31 216 183 102 47 
CCR5 9.0175 8.42125 12.8025 11.48875 0 0 225 0 0 0 
CCR6 8.50875 9.2375 11.335 12.93375 44 45 150 1189 89 46 
CD26 57.55 62.48625 36.325 38.92625 46 49 168 4338 63 40 
CD40 0.7575 0.6575 0.6625 1.2225 43 23 128 536 40 47 
CD48 98.10875 104.165 54.72 62.7475 56 12 161 1719 76 57 
CD5 39.29125 36.045 75.25125 67.13625 47 10 266 1103 71 46 
CD6 28.54125 25.80625 32.85375 32.1475 48 19 290 2251 72 49 
CD74 68.0725 63.30375 74.11375 75.7825 39 13 141 540 44 19 
CDC42SE2 127.65 135.19 156.70375 152.48875 29 43 37 5908 122 39 
CDKN1B 44.0125 38.32875 65.74 61.6575 48 41 150 166 72 55 
CLIC1 53.51625 53.15125 38.7725 45.115 22 53 86 230 11 0 
CLTC 26.62375 29.5325 23.9675 24.345 0 0 378 2492 127 0 
CNN2 8.67375 7.68875 10.2725 10.485 39 23 221 653 70 1 
COMMD7 4.35875 4.34625 5.26125 5.58125 42 14 83 1811 38 48 
CPEB4 9.7225 10.48625 6.4025 6.1475 47 57 231 2560 179 30 
CREBL2 7.86375 7.99375 9.94125 9.68125 51 29 30 1289 143 50 
CREM 44.7525 52.5425 202.63 206.66 53 100 216 3658 156 50 
CRTC3 12.585 12.03 14.05375 14.4225 48 9 356 4228 0 0 
CSF2 170.12625 211.3525 64.11 91.325 42 2 70 114 14 35 
CUL2 9.2425 10.7275 8.38125 7.70625 38 28 247 3703 69 49 
CXCL8 0.425 1.54375 0.625 3.7925 52 18 53 103 87 50 
CXCR5 1.8875 2.005 1.1625 1.2425 47 34 165 468 80 0 
CYTH2 2.33125 1.8975 2.29125 2.515 46 22 201 598 170 51 
DCTPP1 17.2675 18.09125 12.13375 13.0675 30 12 97 222 24 44 
DENND1B 4.89125 4.9075 4.11375 3.8525 40 17 390 10312 303 37 
DGKE 16.78 18.73 27.02125 27.01625 0 11 274 1288 227 40 
DNMT3A 12.48875 11.76375 7.22375 7.4675 0 12 468 2123 91 42 
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DOCK9 31.04875 31.72375 26.8475 23.3775 0 0 8 1667 0 0 
DOK6 5.2875 5.64625 4.165 4.28 0 0 119 10102 304 48 
DPAGT1 12.88625 11.63625 9.83625 9.27125 49 35 177 246 28 0 
DUSP16 19.99 19.7 36.64 37.28375 31 35 326 3609 207 82 
DUSP28 2.19625 1.77875 2.50625 2.63625 0 45 84 144 34 55 
E2F3 7.355 7.37875 6.38125 5.6975 0 0 118 989 148 46 
ECHDC1 11.79625 11.9525 9.3725 8.2625 41 18 133 2182 49 0 
EGR2 197.86 203.23 120.2175 121.855 42 25 195 156 63 48 
EIF3CL 73.66875 79.34 59.08875 63.20875 0 0 0 0 0 0 
ERAP2 19.0375 21.23 13.64875 13.92625 53 48 503 1973 102 36 
ETS1 124.93 129.51625 152.0525 152.275 0 22 16 614 0 0 
EXOC6 6.3875 6.9475 6.75375 5.515 45 14 157 3606 0 0 
EZH2 23.1625 27.0275 17.485 20.1125 0 0 226 3440 27 61 
EZR 142.1775 139.6075 197.61375 199.25625 0 0 0 0 0 0 
F5 25.05125 28.0925 22.38625 20.9725 50 10 1097 3190 111 39 
FADS3 0.745 0.6575 1.80625 1.8075 31 4 203 886 21 57 
FAM134C 6.4325 6.5225 6.8375 7.955 0 7 275 1174 98 41 
FAM213B 4.1125 3.7425 2.70125 2.46625 34 2 138 169 113 0 
FASLG 47.3525 47.40625 14.81625 13.61125 33 10 126 306 58 33 
FBRS 16.3275 17.2125 13.19125 13.91625 47 0 372 534 71 46 
FCGR3B 0.1825 0.0925 0.11 0.25125 49 73 176 331 77 42 
FCMR 22.4275 17.155 30.52375 26.385 39 13 176 734 43 0 
FERMT3 8.58 9.10875 6.37375 7.26125 51 11 375 853 26 0 
FKRP 1.855 1.53 1.43875 2.08625 0 21 253 416 59 40 
FNDC3A 22.315 24.75625 17.89125 17.79 42 34 489 9625 86 36 
FNIP1 60.75625 69.25 56.19125 58.82875 47 12 460 6336 98 45 
FOS 7.61125 8.2975 12.2825 12.98125 37 18 181 100 38 49 
FOSL1 12.67625 13.8375 7.42 7.27625 37 10 121 323 42 0 
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FOSL2 20.99875 24.13125 55.6375 57.9825 0 0 157 782 113 53 
FOXP1 92.74 99.51625 83.7925 86.35875 0 20 28 1234 0 0 
FRYL 45.1475 47.81875 44.71625 42.94625 0 0 1148 4394 89 38 
FTH1 146.36875 132.44125 644.92625 618.415 58 56 90 144 22 0 
FURIN 16.84125 19.155 19.36625 25.745 57 32 61 347 0 0 
FYN 96.0625 97.06 138.69625 134.32375 33 19 195 9002 60 42 
GALC 9.43875 9.85875 15.05 16.03375 45 28 376 2749 90 43 
GART 16.94375 18.62125 15.11 15.14375 0 33 466 1806 56 53 
GFI1 19.1575 20.85375 32.08875 34.99625 24 17 196 443 73 50 
GLS 85.67375 93.4625 72.92125 73.285 38 22 212 3337 205 54 
GNPDA1 11.68875 12.5825 7.08625 7.9425 41 5 139 459 65 35 
GPR18 13.93 16.2425 12.81 11.77625 0 0 180 0 0 0 
GPR183 97.025 111.4075 154.83125 158.77125 0 0 148 0 0 0 
GPR65 17.13 19.53625 32.765 31.01625 34 34 143 198 134 41 
GTF3C2 8.85375 9.795 8.7425 7.94125 56 19 365 1300 33 45 
HDAC7 13.81875 13.0675 8.23 9.4975 37 3 476 1919 58 0 
HLA-B 1042.84625 1018.9725 902.7325 937.99125 108 7 338 332 51 92 
HLA-DQB1 13.16 13.05625 15.4425 16.89125 216 12 320 1644 105 107 
HLA-DRA 14.3675 13.50875 17.56 19.9175 48 12 101 231 20 56 
HLA-DRB1 20.90125 18.51875 25.7075 25.9425 204 28 247 2565 92 268 
HSPA1B 31.1175 29.25875 35.50625 36.9625 51 52 123 0 32 44 
HYOU1 18.83 19.8 14.895 16.00125 59 8 470 806 88 49 
ICAM1 18.5425 23.51 7.2875 10.28625 41 27 297 674 78 0 
IDE 4.49875 5.1775 4.2775 4.02625 33 10 425 5126 105 51 
IFIH1 34.91875 37.81875 24.55125 26.8375 38 23 539 2178 10 42 
IFITM10 0.05 0.02875 0.06 0 65 8 60 760 156 43 
IFNG 632.92 1164.26875 242.44875 496.45125 40 12 56 202 26 49 
IKZF1 157.725 166.2275 141.93875 150.265 43 33 259 3715 282 60 
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IKZF3 73.95375 74.64375 55.75625 58.94875 27 30 208 3947 304 40 
IL10 17.77 17.49875 8.9125 10.77875 38 7 74 199 67 46 
IL10RB 18.57 17.5825 26.0875 24.2625 0 12 144 1424 54 36 
IL13 29.64875 31.64625 41.6625 58.32375 51 3 80 126 66 49 
IL18R1 9.4725 10.28875 15.7975 16.205 38 10 232 1867 91 45 
IL1R2 1.74625 2.19 3.1825 3.8225 64 26 214 1921 16 36 
IL2 317.105 533.93875 85.3525 167.25875 38 6 56 169 13 43 
IL21 5.78625 8.26875 3.46375 3.54875 0 0 46 276 25 30 
IL3 102.58125 121.96125 38.31875 49.21125 59 11 87 131 33 47 
IL5 53.415 55.43 92.9825 93.4825 39 16 74 83 28 45 
IL6ST 26.425 32.08375 21.76875 21.44125 0 28 395 2362 254 45 
IL7R 278.1125 286.45625 488.495 446.68875 44 10 279 1011 181 43 
IMPG2 0.42875 0.56125 0.25625 0.32625 39 14 587 3837 178 47 
INPP5D 11.085 10.2475 13.105 12.645 67 45 462 7217 67 64 
IP6K1 3.68875 3.06125 4.03875 4.3025 37 36 163 2440 130 0 
IRF1 33.75 34.885 21.3625 24.0825 39 10 120 368 101 43 
IRF8 7.995 9.97 2.33375 4.3175 49 4 239 1399 94 63 
ITGAL 43.12125 42.7675 35.76375 33.97625 48 10 533 2192 75 0 
ITGAV 1.71375 1.96625 3.65125 3.81375 0 0 457 2038 230 59 
JAK2 6.28875 8.005 3.62 4.04 53 25 491 7865 72 49 
KDELR2 23.2025 27.31125 18.8175 21.77125 33 21 145 1168 86 58 
KIAA1109 26.9475 29.305 41.77625 39.04375 55 6 1744 7707 15 45 
KIF3B 7.75625 8.555 9.09875 10.44125 29 8 315 2171 163 45 
LGALS9 3.505 3.69875 1.81875 2.33375 52 14 205 994 31 60 
LIF 3.82125 6.06625 2.56375 3.10625 36 13 114 144 150 46 
LMNA 18.7425 17.72 11.4325 12.9325 0 40 480 2310 53 39 
LPXN 73.2575 75.26875 94.035 93.22875 0 36 199 2148 24 41 
LRRC32 6.1225 6.22375 10.00125 9.90875 40 12 403 416 110 64 
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LTA 180.585 191.72125 16.92875 25.4075 41 25 75 58 28 8 
LTB 74.44375 61.1325 30.3525 32.86 43 0 122 194 10 39 
MAML2 18.1675 23.7625 13.78375 15.21875 48 41 329 13643 0 0 
MANBA 2.50625 2.4525 3.50125 3.59875 39 13 439 5624 49 57 
MAP3K8 5.9325 6.81375 10.11 12.5525 63 29 203 1208 40 46 
MAP4 43.5075 46.39375 35.295 37.99 40 21 107 6644 100 0 
MAPKAPK5 7.29 8.85875 5.83375 5.99375 0 0 164 2058 14 41 
MIER1 23.23625 26.93125 22.55 20.04125 0 26 237 2514 240 43 
MMP9 0.0125 0.0025 0.4525 0.35125 43 6 426 363 17 48 
MOB4 59.91375 72.77125 45.3025 50.10125 0 18 13 0 0 0 
NAA25 13.07 15.48 10.805 11.02875 0 0 155 767 105 48 
NBL1 1.0425 0.995 2.14 2.13625 0 60 29 0 0 0 
NBN 11.79125 13.87 10.1675 9.87375 37 32 444 2224 86 47 
NDFIP1 18.0325 20.84875 13.1175 13.46625 44 18 81 1949 116 49 
NFKB1 91.39 107.44125 104.76875 119.1925 34 15 397 4935 43 42 
NFKBIZ 30.7775 37.38375 36.13875 45.67 0 6 295 660 0 0 
NOTCH1 4.1475 4.35 2.25625 2.80875 0 0 1547 3035 102 62 
NOTCH2 12.69875 14.26 11.01125 11.92875 28 37 1070 5908 164 33 
P2RY11 15.145 12.6125 8.10875 9.31875 0 16 5 0 0 0 
PCBD2 2.725 2.66375 3.65 4.1425 26 1 42 2625 92 28 
PDE4A 0.89 1.0825 4.2775 3.805 45 49 543 2155 179 54 
PFKFB3 23.36375 28.605 50.3625 60.015 53 49 294 5342 169 74 
PHACTR2 10.91125 10.8775 20.81625 17.5475 49 23 302 9283 217 0 
PHTF1 4.6875 6.36875 7.50875 8.54125 43 20 365 2452 34 45 
PIM3 62.5025 66.19875 28.40375 37.4125 16 23 183 131 76 51 
PLAU 0.4375 0.86875 0.0975 0.11875 0 0 194 0 33 0 
PLB1 0.54375 0.41 0.8125 1.19125 51 11 803 7799 0 0 
PPIF 14.73 16.1125 10.6225 11.7 42 6 93 298 84 36 
  66 
PRELID1 19.5225 20.8625 16.74375 16.48125 0 18 89 95 0 0 
PRELID3B 40.66375 47.0375 37.325 39.11 0 0 83 0 0 0 
PRKAR2A 2.42875 2.0725 2.745 3.07125 0 13 174 3631 44 41 
PRKCD 6.9725 7.895 5.92 6.11375 34 19 302 1619 20 47 
PSMB8 45.265 46.595 33.1225 35.29 0 8 158 170 19 23 
PTGDR2 1.10875 1.0025 0.34875 0.3325 45 7 172 91 72 0 
PTGER4 37.88375 44.81625 29.96875 32.84375 36 24 207 375 59 45 
PTPN1 16.40875 17.24125 20.2225 22.11 50 26 159 3157 56 0 
PTPRC 560.6825 578.32 861.07875 763.0225 46 18 605 4969 108 37 
PWP2 3.84375 4.25375 3.02 3.00875 0 19 573 1449 40 47 
RAD50 8.1875 8.9125 8.11 7.405 46 27 689 3170 0 0 
RANGAP1 7.06125 6.55875 8.11875 9.1975 50 40 311 2003 102 43 
RASGRP1 56.8575 62.57625 83.2575 80.73625 53 4 288 3248 94 0 
RAVER1 20.0575 20.61125 17.3925 15.65 0 13 390 811 50 0 
REL 59.2125 67.2825 70.33375 77.5175 0 23 254 1790 237 19 
REV3L 11.78875 14.0525 11.61375 10.705 0 33 1332 7509 60 49 
RIPK2 13.17 13.9025 9.665 9.8425 0 46 209 1281 45 38 
RNASEH2C 5.21625 4.13 5.38125 5.35875 39 15 114 103 110 0 
RNASET2 12.20125 11.275 16.155 14.61125 62 22 117 1449 5 49 
RNF145 19.87 21.28625 19.74625 24.31125 49 44 235 2210 68 48 
RORC 3.44 4.485 3.78625 5.72 58 38 266 1084 115 0 
RPAP2 4.58375 5.33625 4.98375 3.98875 0 6 246 3200 57 50 
RPAP3 6.5575 8.53375 6.65125 5.85 49 9 290 1771 74 52 
RSL1D1 104.19125 121.75625 94.21375 92.0625 76 18 307 830 241 62 
S100A10 161.8775 157.3075 117.51125 115.1775 26 24 43 453 19 42 
S100A11 289.02375 277.97625 227.85625 213.49625 39 13 58 137 10 37 
S1PR5 0.4125 0.35625 1.14625 1.11375 50 13 213 162 45 39 
SDCCAG3 4.405 5.08 3.68625 3.67875 0 9 321 582 58 60 
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SELL 81.14875 83.26875 66.795 64.5175 45 17 183 956 61 39 
SELP 0.8225 0.8025 0.555 0.48 57 7 459 1926 20 32 
SENP1 16.74625 19.01125 16.04875 14.67375 0 0 48 465 97 37 
SERBP1 72.44875 81.74875 57.8975 63.175 61 22 173 801 235 58 
SH2B3 18.74125 18.72875 13.4325 12.44375 39 20 320 1691 153 0 
SLAMF1 100.5325 110.96 83.32125 93.7975 57 31 122 872 0 0 
SLAMF7 13.22125 15.43625 7.62375 8.77875 40 22 190 748 74 54 
SLAMF8 0.58375 0.63375 0.22125 0.13375 0 0 2 0 0 0 
SLC1A5 39.70125 41.11375 23.665 28.035 33 60 271 575 30 51 
SLC22A4 1.03875 0.695 1.28 1.4725 57 15 258 661 0 0 
SLC35D1 6.875 7.04875 8.35375 8.17 31 28 174 2035 209 37 
SLC39A8 20.51875 23.82625 32.69875 32.6175 36 37 188 3804 176 83 
SLC43A3 48.5875 77.33625 19.08625 32.26125 48 36 114 451 0 0 
SLC5A6 7.8075 9.59375 7.64625 7.02625 0 11 345 630 38 58 
SNAPC4 3.1775 3.1325 2.2625 2.1275 68 2 976 1491 15 58 
SON 107.31375 122.93125 106.5775 110.74 0 18 1265 1139 132 0 
SP100 53.21125 59.87125 45.36375 41.49875 53 21 251 2639 19 0 
SP110 31.6775 30.78125 25.77375 23.79 0 27 407 2515 43 50 
SP140 22.865 21.51625 18.225 17.71375 0 9 435 4125 49 42 
SP140L 21.7875 20.90375 18.10875 17.19 46 17 325 3416 49 57 
SPRY4 2.88375 2.56125 0.6575 0.54 0 58 203 382 206 62 
STAT1 143.56625 145.75 67.1625 73.9075 51 28 229 2148 83 41 
STAT4 60.9225 68.895 95.7825 102.24875 32 21 248 5229 22 42 
STAT5B 50.7025 54.0725 65.30625 69.7075 31 4 273 3137 127 48 
TAB2 203.6275 218.28875 195.6325 181.75875 0 0 0 890 0 0 
TAGAP 86.15 85.29 60.3725 54.71875 30 35 358 369 65 46 
TAP1 78.345 76.22 41.11 49.89 0 11 364 350 0 0 
TAP2 26.22625 28.7575 15.9575 15.8125 35 7 351 588 198 31 
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TFAM 8.98125 9.7075 6.8325 7.84875 36 34 101 467 174 40 
TGFBR3 7.06375 6.97 15.32375 14.27125 39 8 0 367 0 0 
THEMIS 25.62 27.4025 18.9425 17.53 51 17 363 9097 71 55 
TMEM50B 15.1825 14.29625 20.1425 18.9375 40 9 70 1318 79 53 
TMEM9 1.59625 0.8375 1.17875 1.94625 0 0 56 831 54 62 
TNF 1052.3125 1286.32625 247.55375 342.72875 9 13 96 74 45 31 
TNFAIP3 56.635 66.42 90.05 91.4075 0 2 359 549 79 44 
TNFRSF14 10.58125 9.91 7.5825 7.4975 0 0 188 460 147 0 
TNFRSF9 15.545 16.78125 30.69125 32.84875 36 11 134 1057 220 43 
TNFSF8 262.02875 285.77875 198.4675 197.96875 57 15 118 1417 160 38 
TPPP 1.22125 1.27875 2.47 2.39625 47 4 144 1760 359 61 
UBE2D3 147.98625 162.2975 127.3825 123.565 0 83 37 1461 0 0 
USP12 19.4925 23.105 17.095 17.74125 0 15 110 2534 126 45 
USP36 34.18125 36.06 49.16 45.1 0 1 723 2250 113 48 
VCL 19.7675 19.55625 13.12875 12.61 46 11 467 4777 81 0 
VMP1 187.17375 210.935 169.69875 170.51 0 8 131 5033 28 0 
WSB1 59.98625 65.2775 96.5075 86.6825 0 35 228 842 61 41 
ZDHHC11 3.8925 3.99125 7.17375 6.905 0 0 112 2091 82 38 
ZFP36L1 208.62625 202.07375 138.36625 126.01625 51 54 173 373 71 38 
ZFP36L2 18.19125 18.06625 34.6575 30.67 0 29 257 58 0 0 
ZMIZ1 17.6675 17.57125 13.3325 13.3225 21 38 488 12034 216 58 
ZNF831 1.74125 1.63125 2.62 2.31625 42 0 920 2610 195 43 
ZSWIM8 12.83 10.88625 11.80625 12.9675 60 19 715 529 5 0 
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Table 6. Potentially deleterious exonic DSVs in DE genes and in LD with Tag-SNPs 
RS ID GENE TAG SNP LD R2 POLYPHEN SCORE W POLYPHEN 
SIFT 
SCORE W SIFT 
CAROL 
PREDICTION 
CAROL 
SCORE 
rs1805078 GALC rs8005161 0.594 0.989 4.510 0.973 3.612 Deleterious 0.999 
rs11556887 SP110 rs6716753 0.270 0.999 6.908 0.94 2.813 Deleterious 1.000 
rs1131992 SDCCAG3 rs10781499 0.236 0.986 4.269 0.859 1.959 Deleterious 0.993 
rs3812577 SDCCAG3 rs10781499 0.221 0.986 4.269 0.871 2.048 Deleterious 0.993 
rs11230562 CD6 rs11230563 0.194 0.998 6.215 0.96 3.219 Deleterious 1.000 
rs45604939 FNDC3A rs2026029 0.180 0.994 5.116 0.996 5.521 Deleterious 1.000 
 
  
  70 
Table 7. Promoter region DSVs in DE genes that potentially alter TF Binding sites, and are in strong LD with tag-SNPs 
RS ID GENE REGION TAG SNP LD R2 TF 
rs306587 MAP3K8 upstream rs1042058 1 RXRA, XBP1, POU2F2, ELF1, SP100, GFI1, RREB1, SP4, EGR1, KLF7 
rs630923 CXCR5 upstream rs630923 1 SRF, TGIF1, ZBTB7A, PRDM1, PLAG1, EGR1, HOXB3, RXRA, VDR, MYB, CTCF, SP100, HMBOX1 
rs28667727 GPR65 upstream rs8005161 1 MAF, SMAD4, SMAD3, GCM1, HIC1, TCF12, RFX5, VDR, MYB, EGR1, SP4, SP1 
rs34953890 PDE4A upstream rs11879191 1 GFI1, MYC, PRDM1, RXRA, PLAG1, ESR2, VDR, NANOG, FOXP3, CEBPG, ZBTB3 
rs1494571 IL7R downstream rs3194051 1 ZNF143, SP4, ZBTB7A, SP1, EGR1, KLF7, YY1, MAF, ZBTB33, POU2F2, GFI1 
rs2769346 RNASET2 upstream rs1819333 1 MAF, ZEB1, MYC, POU2F2, FOXJ2, MTF1, FOXP1, EGR1, ZFX, GCM1, ZBTB3, HIC1 
rs2149083 RNASET2 upstream rs1819333 0.99619 VDR, MTF1, ESR2, FOXJ2, ZBTB3, MAF, FOXP1, SP1, FOXK1, ZFX, MYC, HIC1, ZEB1, POU2F2 
rs2149084 RNASET2 upstream rs1819333 0.99619 MYC, MAF, ZEB1, POU2F2, GFI1, MTF1, ZBTB3, HIC1, PRDM1, ELF1, FOXK1 
rs11567685 IL7R upstream rs3194051 0.995244 MAF, POU2F2, ZNF143, POU6F1, HIC1, AHR, RFX5, SP4, ELF1, FOXP1, ZEB1, FOXJ2, ZFX, SP1 
rs8011558 ZFP36L1 upstream rs194749 0.994497 NANOG, BBX, RXRA, HLF, ARID5A, ARID5B, SRF, POU2F2, SMAD4, YY1, CEBPB 
rs4934730 CREM upstream rs34779708 0.98712 ATF3, XBP1, BATF, ATF2, RFX5, RREB1, TGIF1, FOXP3, HOMEZ 
rs35388511 CUL2 downstream rs34779708 0.982761 POU2F2, RREB1, ZBTB7A, CEBPB, ATF6, EGR1, FOXJ2, FOXP1, FOXK1, ATF3, MYC, RXRA, YY1, BHLHE40 
rs34815241 CUL2 downstream rs34779708 0.982761 MTF1, RXRA, ZBTB3, CEBPB, AHR, MXI1, MYC, BHLHE40, GFI1, ZNF143, ESR2, ZBTB33, XBP1, ZEB1, VDR 
rs16935880 CREM upstream rs34779708 0.982761 RXRA, AHR, ZEB1, GFI1, RREB1, SMAD3, ATF6, RFX5, ZBTB3, ATF3 
rs9338188 MAP3K8 upstream rs1042058 0.979507 VDR, PRDM1, SPIB, ELF1, SRF, ESR2, RFX5, GFI1, SMAD3 
rs2384275 CUL2 downstream rs34779708 0.978464 BBX, MTF1, XBP1, E4F1, GFI1, MAF, ATF3, ZBTB3, TGIF1, SMAD3, RXRA 
rs3829110 SNAPC4 downstream rs10781499 0.974351 RXRA, POU6F1, SPIB, ZFX, HOMEZ, MAF, PRDM1, BACH1, ESR2, HIC1, TGIF1, YY1, FOXK1 
rs10781500 SNAPC4 downstream rs10781499 0.974351 POU2F2, CEBPB, HIC1, YY1, ARID5A, SP100, HLF, DBP 
rs3829111 SNAPC4 downstream rs10781499 0.974351 TGIF1, MYC, EOMES, PBX3, YY1, MXI1, PLAG1, ZFX, RXRA, ARNT, MTF1, ATF2, HIC1, MAF 
rs3812558 SNAPC4 downstream rs10781499 0.969998 CEBPB, BACH1, ZBTB33, POU2F2, POU6F1, PRDM1, SP4, SRF, YY1, FOXJ2, HIC1, RXRA 
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rs7139746 FNDC3A downstream rs2026029 0.947661 GFI1, FOXJ2, RXRA, ZFX, BACH1, BACH2, MAF, SPIB, FOXK1 
rs13015714 IL18R1 upstream rs6708413 0.945823 POU2F2, FOXP3, ELF1, FOXP1, PRDM1, FOXK1, SPIB, FOXJ2, CEBPB, RXRA, HLF, RREB1, GFI1 
rs2027030 KIF3B downstream rs6142618 0.933081 FOXP1, POU2F2, ARID5A, FOXJ2, EGR1, HOMEZ, SP4, MAF, POU6F1, BBX, HOXB3, FOXK1, LHX4 
rs948788 DOK6 downstream rs727088 0.898146 ELF1, ATF3, PRDM1, YY1, ZNF143, SPIB, RXRA, POU2F2, VDR, MAF, RFX5 
rs2365358 DOK6 downstream rs727088 0.898146 SP4, CRX, ZFX, PRDM1, MYC, EGR1, ZEB1, SP1, HIC1, KLF7, SMAD4, VDR, EOMES, FOXP1, FOXJ2 
rs75203923 DOK6 downstream rs727088 0.898146 FOXP1, ZEB1, FOXJ2, FOXK1, VDR, EGR1, BHLHE40, RXRA, SP1, MYC, SP4, ARNT, GCM1, HIC1 
rs3812560 SNAPC4 downstream rs10781499 0.85618 VDR, ESR2, MAF, SMAD4, RXRA, ELF1, ZBTB7A, CTCF, RFX5, ZNF143, MYB, SP1 
rs2069776 IL2 downstream rs7657746 0.853055 XBP1, MAF, ATF3, CEBPG, ZBTB3, BBX, GCM1, RXRA, HOMEZ, HLTF, AHR, YY1, HIC1 
rs3812575 SNAPC4 upstream rs10781499 0.840385 SRF, RXRA, MYC, PRDM1, HLTF, RREB1, ESR2, SP4, KLF7, HIC1, RFX5 
rs1887428 JAK2 upstream rs10758669 0.82493 FOXP3, EGR1, RFX5, ZEB1, VDR, AHR, RREB1, SP1, ATF3, ZNF143, BACH2 
rs4957083 TPPP downstream rs4957048 0.818356 FOXJ2, SP4, SP1, KLF7, CTCF, EGR1, POU2F2, MYC, ZBTB7A, EOMES, ZEB1 
rs72705102 TPPP downstream rs4957048 0.812482 VDR, ZEB1, SMAD3, E4F1, RXRA, RREB1 
rs1465788 ZFP36L1 upstream rs194749 0.808403 LHX4, RXRA, HIC1, NANOG, SMAD3, MYB, TGIF1, SRF, ZBTB7A, MYC, RREB1, MXI1, RFX5, GFI1, HLTF 
rs28665408 DOK6 downstream rs727088 0.803789 GFI1, PRDM1, CEBPB, CEBPG, YY1, HOMEZ, FOXK1, RFX5, FOXJ2, FOXP1, POU2F2, CTCF 
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Table 8. SNPs that potentially alter miRNA Binding sites and are in strong LD with tag-SNPs 
RS ID GENE REGION TAG SNP LD R2 MIRNA DE GENE 
rs7603250 IL18RAP UTR3 rs6708413 1 miR-148a-3p, miR-181a-5p, miR-25-3p, miR-3138 YES 
rs1564823 CPEB4 UTR3 rs17695092 1 miR-206, miR-3138 YES 
rs9611591 TOB2 UTR3 rs727563 1 miR-629-5p NO 
rs11648503 ZFP90 UTR3 rs1728785 1 miR-155-5p, miR-25-3p, miR-324-3p, miR-370-3p, miR-628-5p YES 
rs14316 TM9SF4 UTR3 rs6142618 1 miR-135b-3p, miR-1827, miR-196a-5p, miR-3138, miR-629-5p NO 
rs835576 NOTCH2 UTR3 rs3897478 1 miR-181a-5p, miR-206 NO 
rs699779 NOTCH2 UTR3 rs3897478 1 miR-125a-5p, miR-125b-5p, miR-370-3p, miR-502-5p NO 
rs17696407 CPEB4 UTR3 rs17695092 1 miR-335-5p YES 
rs17780256 SLC39A11 UTR3 rs17780256 1 miR-1307-3p, miR-510-5p YES 
rs72812861 CPEB4 UTR3 rs17695092 1 miR-335-5p YES 
rs727088 CD226 UTR3 rs727088 1 miR-181a-5p, miR-502-5p YES 
rs7559479 IL18RAP UTR3 rs6708413 1 miR-370-3p YES 
rs1976074 CPEB4 UTR3 rs17695092 1 miR-370-3p, miR-502-5p YES 
rs449454 NDFIP1 UTR3 rs6863411 0.995622 miR-148a-3p YES 
rs3087783 ZFP90 UTR3 rs1728785 0.993747 miR-155-5p, miR-1827, miR-196a-5p, miR-3162-5p YES 
rs60474474 PTPN2 UTR3 rs1893217 0.992134 miR-125a-5p, miR-135b-3p, miR-148a-3p, miR-155-5p, miR-25-3p, miR-324-3p, miR-628-5p NO 
rs13900 CCL2 UTR3 rs3091315 0.989913 miR-135b-3p, miR-3162-5p, miR-335-5p NO 
rs7515633 TNFRSF14 UTR3 rs6667605 0.988174 miR-148a-3p, miR-184, miR-3138 YES 
rs40837 IL27 UTR3 rs26528 0.987515 miR-135b-3p, miR-185-5p, miR-3162-5p, miR-335-5p, miR-510-5p, miR-629-5p NO 
rs17591857 CREM UTR3 rs34779708 0.987161 miR-370-3p YES 
rs17591781 CREM UTR3 rs34779708 0.987161 miR-155-5p, miR-25-3p YES 
rs12042319 DOCK7 UTR3 rs1748195 0.986678 miR-181a-5p, miR-196a-5p, miR-628-5p NO 
rs10910090 TNFRSF14 UTR3 rs6667605 0.984193 miR-181a-5p, miR-370-3p, miR-502-5p YES 
rs41312668 SLC30A7 UTR3 rs11583043 0.980255 miR-135b-3p, miR-196a-5p NO 
rs17100939 SLC30A7 UTR3 rs11583043 0.97522 miR-184 NO 
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rs7118 ZFP90 UTR3 rs1728785 0.969546 miR-148a-3p, miR-155-5p, miR-206, miR-25-3p, miR-370-3p, miR-628-5p YES 
rs1878036 TSPAN14 UTR3 rs7097656 0.961809 miR-155-5p YES 
rs6061216 PLAGL2 UTR3 rs6142618 0.94972 miR-155-5p, miR-25-3p YES 
rs583121 LSM14A UTR3 rs587259 0.947327 miR-184, miR-191-5p NO 
rs1056441 LIME1 UTR3 rs6062504 0.945447 miR-135b-3p, miR-1827, miR-191-5p, miR-196a-5p, miR-3138, miR-502-5p NO 
rs9950174 DOK6 UTR3 rs727088 0.940146 miR-155-5p, miR-3138 YES 
rs202639 PHF5A UTR3 rs727563 0.937457 miR-206 NO 
rs2032933 RMI2 UTR3 rs529866 0.936696 miR-1307-3p, miR-191-5p NO 
rs1568681 IL18R1 UTR3 rs6708413 0.935242 miR-185-5p, miR-3162-5p YES 
rs39602 LNPEP UTR3 rs1363907 0.929415 miR-135b-3p, miR-196a-5p, miR-3138, miR-3162-5p, miR-629-5p NO 
rs1045100 ATG16L1 UTR3 rs6752107 0.913202 miR-206 NO 
rs174546 FADS1 UTR3 rs4246215 0.911455 miR-25-3p, miR-324-3p, miR-502-5p NO 
rs503279 FUT2 UTR3 rs516246 0.892695 miR-25-3p, miR-370-3p NO 
rs570794 FUT2 UTR3 rs516246 0.892695 miR-1307-3p, miR-148a-3p, miR-155-5p, miR-184, miR-25-3p, miR-370-3p NO 
rs571689 FUT2 UTR3 rs516246 0.892695 miR-196a-5p, miR-3162-5p, miR-510-5p, miR-629-5p NO 
rs507855 FUT2 UTR3 rs516246 0.889292 miR-125b-5p, miR-335-5p, miR-629-5p NO 
rs507766 FUT2 UTR3 rs516246 0.889292 miR-125a-5p, miR-125b-5p NO 
rs632111 FUT2 UTR3 rs516246 0.888496 miR-125b-5p, miR-510-5p NO 
rs504963 FUT2 UTR3 rs516246 0.888496 miR-184, miR-185-5p, miR-191-5p NO 
rs1130161 HLA-DQA1 UTR3 rs477515 0.887342 miR-185-5p NO 
rs17367849 POLR3H UTR3 rs727563 0.886313 miR-1307-3p YES 
rs4625 DAG1 UTR3 rs3197999 0.883128 miR-191-5p NO 
rs603985 FUT2 UTR3 rs516246 0.879409 miR-206, miR-3162-5p NO 
rs485073 FUT2 UTR3 rs516246 0.879409 miR-206 NO 
rs1857335 TNFSF15 UTR3 rs6478106 0.876764 miR-125a-5p, miR-125b-5p, miR-191-5p, miR-196a-5p, miR-324-3p, miR-370-3p, miR-502-5p NO 
rs6997 TCTA UTR3 rs3197999 0.871181 miR-135b-3p, miR-1827, miR-196a-5p NO 
rs9538 ZC3H7B UTR3 rs727563 0.868642 miR-125a-5p, miR-125b-5p, miR-185-5p, miR-191-5p, miR-25-3p, miR-502-5p, miR-510-5p, miR-628-5p YES 
rs3208703 KIF21B UTR3 rs7554511 0.852169 miR-181a-5p, miR-3138, miR-324-3p, miR-370-3p, miR-628-5p NO 
rs736106 DUSP16 UTR3 rs11612508 0.847733 miR-155-5p, miR-184, miR-3138 YES 
rs8139993 DESI1 UTR3 rs727563 0.847436 miR-629-5p YES 
rs7592344 MARS2 UTR3 rs1440088 0.845669 miR-185-5p NO 
rs1054609 ZPBP2 UTR3 rs12946510 0.844528 miR-125b-5p NO 
rs10457487 RSPO3 UTR3 rs9491697 0.834573 miR-135b-3p, miR-196a-5p NO 
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rs699780 NOTCH2 UTR3 rs3897478 0.833398 miR-148a-3p, miR-1827, miR-502-5p, miR-510-5p NO 
rs5758364 PHF5A UTR3 rs727563 0.832553 miR-181a-5p, miR-502-5p NO 
rs9611577 TEF UTR3 rs727563 0.823785 miR-1827, miR-191-5p, miR-196a-5p, miR-3138, miR-324-3p, miR-370-3p NO 
rs174544 FADS1 UTR3 rs174537 0.822688 miR-1307-3p, miR-206, miR-502-5p NO 
rs13001714 IL1RL1 UTR3 rs13001325 0.820097 miR-155-5p YES 
rs12712142 IL1RL1 UTR3 rs13001325 0.820097 miR-3138 YES 
rs72707016 TPPP UTR3 rs4957048 0.818356 miR-206 YES 
rs28364691 TPPP UTR3 rs4957048 0.818356 miR-181a-5p, miR-324-3p, miR-370-3p, miR-502-5p, miR-510-5p YES 
rs7558 TPPP UTR3 rs4957048 0.818356 miR-1307-3p, miR-510-5p YES 
rs3762951 TPPP UTR3 rs4957048 0.818356 miR-125a-5p, miR-125b-5p, miR-148a-3p, miR-206, miR-324-3p, miR-370-3p, miR-502-5p, miR-510-5p YES 
rs1260631 LSM14A UTR3 rs587259 0.818352 miR-125a-5p, miR-125b-5p NO 
rs1790974 DOK6 UTR3 rs727088 0.815421 miR-206, miR-3138 YES 
rs72707007 TPPP UTR3 rs4957048 0.812482 miR-125a-5p YES 
  
 
Table 9. DSVs that alter potentially alter splice-sites and are in LD with tag-SNPs 
RS ID GENE FUNCTION TAG SNP LD R2 
rs8373 ZFP91 splicing rs11229555 1 
rs80212515 MUC19 splicing rs11564258 1 
rs11078928 GSDMB splicing rs12946510 0.825071 
rs80212515 MUC19 splicing rs148319899 0.81926 
rs2004640 IRF5 splicing rs4728142 0.654786 
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4.3.6 Effects of PGE2 on expression of isoforms in genes inside IBD-associated regions 
An important aspect of gene regulation is the differential expression of different gene isoforms 
(splice variants) in response to different stimuli. For example, genes expressed in many cancers 
VHHPWRKDYHVKRUWHU¶-UTRs (Mayr & Bartel, 2009), possibly avoiding miRNA silencing. We 
used RSEM to detect isoforms in our samples and edgeR to identify the differentially expressed 
isoforms. Overall, we found 1,122 genes with 1,349 isoforms expressed at different levels in at 
least one of the group comparisons (edgeR multigroup comparison / FDR < 0.05) (Table 4). In 
agreement with the gene model-based results described above, PGE2 seems to be the main factor 
contributing to differential expression of isoforms, since the comparison PGE2-treated vs non-
PGE2 treated cells give the highest number of differentially expressed isoforms (Table 4). 
CREM, for example, is a gene with significant over-expression of isoforms NM_182720 (Refseq 
variant 7), NM_182717 (Refseq variant 4), NM_182719 (Refseq variant 6), NM_182718 (Refseq 
variant 5), NM_182723 (Refseq variant 10) in PGE2-stimulated cells.  CREM plays a key role in 
the regulation of immune responses, including the Th17 immune response (Hedrich, Crispin, et 
al., 2012; Hedrich, Rauen, Kis-Toth, Kyttaris, & Tsokos, 2012; Koga et al., 2014; Lippe et al., 
2012; Rauen, Hedrich, Juang, Tenbrock, & Tsokos, 2011; Rauen, Hedrich, Tenbrock, & Tsokos, 
2013). The expression of different CREM isoforms is likely to be the product of activation of 
distinct promoters. Therefore, we assessed whether any SNPs inside the different CREM 
promoters can alter transcription factor binding sites. Two SNPs located in the various CREM 
promoters were predicted to alter one or more transcription factor binding sites and were in LD 
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with IBD tag SNPs (Table 7). Other immune response genes with differential expression of 
isoforms include TNFAIP3, IL4R, CCR4 and CCL4L2. 
4.4 DISCUSSION 
Our results show that PGE2 induces differential expression of more genes in activated effector 
memory T cells than interleukins IL1ȕ and IL23 combined, and that its presence/absence drives 
major differences in gene expression with or without co-stimulation by IL23 and IL1ȕ
Differential expression analysis reveals that PGE2 changes the expression levels of many genes 
relevant in IBD. In addition to genes differentially expressed in response to PGE2, we also found 
that many genes express alternatively spliced isoforms, such as CREM, which is known to play a 
role in modulating key cytokine gene transcription.  Since PGE2 is a key mediator in IBD, this 
finding points to a potential mechanism for IBD facilitation. 
We also performed extensive analysis to identify genomic variants that can potentially 
affect the function of genes that are regulated by PGE2 and potentially relevant in IBD. Our goal 
was to identify a tractable number of DSVs that are potentially functional.  Therefore, we took an 
innovative data-driven approach which combines RNA-Seq data, publicly available GWAS 
results, and state-of-the-art computational tools. 
Only a small number of non-synonymous exonic variants that were in moderated linkage-
disequilibrium with IBD tag-SNPs were identified. These findings corroborate the observation 
that DSVs in non-coding, presumably regulatory regions of the genome comprise the majority of 
DSVs associated with most complex diseases (Hindorff et al., 2009).  
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Therefore, we focused our analysis on the identification of regulatory functional variants. 
,QWKH¶875RI'(JHQHVZHIRXQG'69VWKDWSRWHQWLDOO\DOWHUPL51$ELQGLQJVLWHVDQGDUH
in strong LD with IBD-tag SNPs. Two of these DSVs (rs7559479, rs7118) have already been 
associated with other complex diseases or modulation of immune response. The presence of SNP 
rs7559479, ORFDWHGLQWKH¶875RIthe IL18RAP gene, was statistically associated with higher 
expression of IL18. This is in agreement with our analysis which shows that rs7559479 disrupts 
binding of miRNA has-miR-370-3p, thus altering expression of IL18 (Martinez-Hervas et al., 
2015). A recent study has shown that SNP rs7118 in the ¶875 RI =)3 is statistically 
associated with UC and that it potentially disrupts microRNA binding sites (Arnold, Ellwanger, 
Hartsperger, Pfeufer, & Stumpflen, 2012). 
We also identified DSVs in upstream, downstream ¶875 DQG LQWURQLF regions that 
potentially alter transcription factor binding sites. Several of the identified DSVs (rs63093, 
rs1494571, rs11567685 and rs13015714) have been shown to be associated with other complex 
diseases. SNP rs63093 has been shown to create a transcription factor binding site for MEF2C, 
thus reducing CXCR5 promoter activity (Mitkin, Muratova, Schwartz, & Kuprash, 2016). Our 
analysis did not consider TF MEF2C, as this transcription factor is not expressed in our samples. 
However, this does not invalidate our results as DSVs can alter binding for multiple TFs at the 
same time. DSV rs1494571 has been shown to be statistically associated with modulation of 
vaccine-induced immunity to measles (Haralambieva et al., 2011) and with lymphocyte 
development in non-hodgkin lymphoma (Schuetz et al., 2013). Studies have shown an 
association between snp rs511567685 and multiple sclerosis in Iranian and Jordanian patients 
(Haj, Nikravesh, Kakhki, & Rakhshi, 2015; Ibayyan et al., 2014), whereas rs13015714 is 
associated with IBD and celiac disease (Koskinen et al., 2009; Latiano et al., 2013). The activity 
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of IL18R1 was shown to have a dose-dependent correlation with rs13015714, which could be an 
effect of TF binding alteration (Koskinen et al., 2009). 
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5.0  CONCLUSIONS, LIMITATIONS AND FUTURE WORK 
5.1 CONCLUSIONS 
Functional annotation of DSVs is crucial to the understanding of the etiology of complex disease. 
Computational methods and pipelines capable of analyzing and predicting the function of DSVs 
from large omics datasets are in great need. This dissertation has presented a novel algorithm that 
can accurately predict the effect of 3’UTR DSVs in miRNA binding. A new pipeline for the 
functional prioritization of DSVs obtained from omics data is also described and tested. 
The is-mirSNP algorithm uses a novel approach for predicting the effect of 3’UTR DSVs 
on miRNA binding. The energy-binding approach used by is-miRSNP allows for the empirical 
calculation of background distributions that are the foundation of a statistically sound approach to 
the problem. The results obtained from is-mirSNP are easy to interpret, and greatly facilitate the 
task of variant prioritization. Experiments performed using an unbiased, manually curated 
validation set of experimentally validated DSVs-miRNA showed that is-mirSNP outperform all 
other existing methods The pipeline for functional annotation of DSVs presented in this 
dissertation utilizes a LD-based approach for the identification of variants related to the problem 
being studied. The pipeline can analyze RNA-seq data from raw data, and uses state-of-the-art 
computational tools for assigning function to DSVs. The analysis pipeline here presented can be.
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applied to any set of RNA-Seq and GWAS datasets, requiring only the modification of parameters 
unique to the design of the data being analyzed. All algorithms and methods used in the pipeline 
are of publicly available, and can, therefore, be utilized by any user. The pipeline performance was 
tested in an IBD-related dataset. RNA-Seq analyses identified biologically relevant genes and 
isoforms that are differentially expressed in the presence of PGE2. Functional annotation of DSVs 
assigned function to variants already known to be related to IBD, and new DSVs related to genes 
and processes potentially relevant in IBD were identified and functionally annotated. 
In conclusion, this dissertation presented novel computational methods that can accurately 
assign function to DSVs related to diseases. These algorithms use novel approaches and solve 
existing informatics problems. The impact of the work described here lies in the future use and 
application of these computational tools to new and existing biological datasets.  
5.2 LIMITATIONS 
The results presented in this dissertation suggest that is-miRSNP is an accurate method for 
predicting DSVs that affect miRNA binding sites. The following limitations need to be taken into 
consideration when interpreting the results here presented:  
a. The validation dataset used to estimate the accuracy of is-miRSNP contains only 23 
variants. The small size of the validation dataset is a direct consequence of the lack of studies that 
experimentally validated the effect of DSVs on miRNA binding. 
b. The false-positive rate of the is-miRSNP algorithm could not be calculated due to the 
lack of true-negative DSV-miRNA data. This is the consequence of a well-known problem in the 
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biomedical literature: papers are biased towards positive results and rarely report failed 
experiments (Dickersin et al., 1987) 
The proposed pipeline for prioritization and functional evaluation of DSVs could identify 
variants that are potentially biologically meaningful in IBD, but the following limitations need to 
be considered: 
a. Pipeline requires data from a biological meaningful GWAS study, which might not be 
available. 
b. Functionally annotated DSVs were not experimentally validated.  
5.3 FUTURE WORK 
The work presented in this dissertation directly leads to the following future directions: 
5.3.1 Expand is-miRSNP to predict effect of INDELS  
The insertion or the deletion of bases in DNA (INDEL) are a common type of genetic variation 
although not as common as single nucleotide variations (Gudbjartsson et al., 2015). INDELs have 
been implicated in complex disease, and can have similar effects as those shown by single-point 
mutations, as they can potentially affect protein coding sequences and alter miRNA and TF binding 
sites. Therefore, the functional annotation of INDELs is important in the understanding of disease 
etiology. Currently, the is-miRSNP algorithm can only predict the effect of 3’UTR single point 
variation, and the expansion of the algorithm so that it can accurately predict the effect of INDELs 
in 3’UTR would greatly enhance its applications. Modifications in is-miRSNP so that it can 
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support the prediction of INDELs would mainly involve the adjustment of the length of mutated 
and reference sequences so that it can utilize the same background distributions currently used by 
SNPs. Correction of the sequence length for binding energy calculation is crucial as binding energy 
will change proportionately with the size of the sequence. 
 
5.3.2 Investigate is-miRSNP background distributions 
The is-miRSNP algorithm requires the pre-computation of empirical background distributions, and 
the computation of such distributions are the most intense computational step of the algorithm. 
The background binding distributions and the distributions of the log-ratio of the p-value ratios 
need to be calculated for every new miRNA added to the predictions. Therefore, the algorithm 
performance and usability would improve if empirical distributions could be modelled and 
generalized. Modelling and generalization of the distributions would require further investigation 
of the similarities and differences in the behavior of the binding of the different miRNAs. 
5.3.3 Expand is-miRSNP prediction to other organisms 
Pre-clinical and translational medical research is often done in animal models, therefore an 
algorithm capable of predict the effect of 3’UTR DSV on miRNA binding would greatly benefit 
the scientific community. Organism-specific background distribution for other organisms needs to 
be computed before the algorithm is up to the task. In addition, datasets of experimentally validated 
variants that affect miRNA binding will need to be evaluated to assess the algorithm performance 
in different organisms.  
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5.3.4 Expand pipeline for functional prioritization of DSVs to integrate different omics 
data types 
The pipeline for functional annotation of DSVs would benefit from the integration of other omics 
data types. The ENCODE project has shown that RNA production and processing is quantitatively 
correlated with transcription factor binding at gene promoters and with the state of the chromatin 
(Consortium, 2012)  Therefore, integration of ChiP-Seq and ATAC-Seq results to the pipeline 
would provide a more accurate picture of the current transcriptional state of the samples, that would 
ultimately lead to better functional predictions of identified DSVs. 
5.3.5 Add variant calling step to RNA-Seq analysis 
Recent work has shown that variants can be accurately called from RNA-Seq data (Piskol, 
Ramaswami, & Li, 2013; Sun, Bhagwate, Prodduturi, Yang, & Kocher, 2016; C. Wang et al., 
2014). Adding a variant-calling step to the pipeline for functional prioritization of DSVs would 
leverage the usage of RNA-Seq data, and help in the integration of  RNA-Seq results with existing 
GWAS datasets. A variant calling step would specially benefit the case where disease-normal 
paired samples (i.e. tumor-normal pairs, or disease-control samples) are being analyzed as variants 
present in normal samples could be immediately removed from analysis and variants present only 
in disease could be assigned higher importance.  
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